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GENERAL INTRODUCTION 
Thesis Organization 
This thesis begins with a general introduction including objectives, hypotheses, 
specific aims, limitations, and the significance of the proposed study followed by a review of 
literature, a manuscript, general conclusions, and references. 
Objectives 
1) The primary objective of this study is to determine the relationship between 
atherosclerotic cardiovascular disease (CVD) risk factors, particularly oxidative 
stress indices, central adiposity, and body iron stores in postmenopausal women. 
2) The secondary objective of this study is to determine whether soy isoflavones 
would reduce the risk of atherosclerotic CVD in postmenopausal women. 
Hypotheses 
1) Oxidative stress and central adiposity is positively associated in postmenopausal 
women. 
2) Excess body iron stores induce oxidative stress thereby increasing CVD risk. 
3) Soy isoflavones will reduce oxidative stress by improving antioxidant status and 
reducing oxidative damage in postmenopausal women, thus reducing CVD risk. 
(These data will not be is not available until 2008). 
Specific Aims 
1) To determine the relationship between oxidative stress, as measured by 
erythrocyte antioxidant enzymes [catalase (CAT), superoxide dismutase (SOD), 
and glutathione peroxidase(GPX)] and oxidative damage indices [oxidized LDL 
(oxLDL), urinary isoprostanes (PGF2a), protein carbonyls, and 8-hydroxy-2'-
deoxyguanosine (8-OHdG)] with body fat in postmenopausal women, taking into 
account additional risk factors including dietary intake and other associated risk 
factors (Figure 1). 
2) To determine the relationship of serum ferritin with oxidative stress and body fat, 
as measured by dual-energy x-ray absorptiometry (DXA) in postmenopausal 
women. 
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Figure 1. Conceptual framework of primary objective 
Central 
Adiposity 
Oxidative 
Stress 
Iron 
Stores 
3) To determine whether isotlavones reduce CVD risk as measured by oxidative 
stress indicators: antioxidant enzymes (CAT, SOD, and GPX) alld oxidative 
damage indices (oxLDL, PGF2a, protein carbonyls, and 8-OHdG) in 
postmenopausal women. 
Limitations 
There are several limitations to our study objectives. The primary objective is an 
observational study and is not causal. In addition, the women in our study are considered 
healthy and may not accurately represent the entire population. In addition, the correlations 
among CVD risk factors in these women may be stronger if the women were obese, diabetic, 
dyslipidemic, or had elevated iron stores. 
The secondary objective cannot be completed until completion of the parent project in 
2008. The laboratory analyses are complete; however, statistical analyses according to 
treatment will not be conducted until completion of the three-year clinical trial. The National 
Institutes of Health, the parent project's funding source, does not allow unblinding of data 
prior to trial completion. 
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Significance of Study 
Women axe at an increased risk of CVD after menopause due to a decrease in 
circulating estrogen concentrations, elevated iron stores, and increased abdominal fat 
accumulation. In addition, increased oxidative stress and decreased oxidative defenses after 
menopause contribute to a rise in CVD risk. Excess iron has been associated with increased 
oxidative damage, contributing to an increased risk of CVD. 
Soy foods contain compounds, such as isoflavones, which are thought to exert 
antioxidant effects and may protect women from heart disease. However, the protective 
mechanism by which isoflavones act is unclear. Isoflavones may provide protection from 
heart disease by improving antioxidant enzymes or by decreasing oxidative damage. 
4 
REVIEW OF LITERATURE 
Cardiovascular Disease 
Cardiovascular disease (CVD) is the major cause of illness and death in men and 
postmenopausal women, particularly in Western societies. About 13 million Americans have 
CVD, 1.5 million have a myocardial infarction each year, and approximately 450,000 die of 
CVD each year (American Heart Association 2000). Over the past couple of decades, there 
has been much interest and research on the etiology of CVD, including environmental, 
lifestyle, and genetic factors. However, it has been more recent that CVD has been defined 
as having an inflammatory etiology component. While high total cholesterol (TC) 
concentration contributes to increased CVD risk, cholesterol may also be involved in the 
pathogenesis of CVD via inflammatory mechanisms. Adhesion molecules, cytokines, and 
oxidative stress may also contribute to the inflammatory state of CVD (1~1eng 2006). 
Therefore, therapies directed at these markers may have potential beneficial effects in 
reducing and treating CVD . 
Risk Factors 
Many risk factors are associated with CVD; some are modifiable and others are 
nonmodifiable. CVD is a condition with multiple etiologies, and the modifiable risk factors 
are of particular importance in reducing CVD risk. 
Non-modifiable 
There are nonmodifiable risk factors for CVD including aging, male gender, and a 
positive family history (Mosca et al. 2002). CVD has traditionally been considered a disease 
targeted towards middle-aged men; however, it has a high prevalence in women, particularly 
after menopause. The number of deaths from CVD in women after 65 years of age surpasses 
men by 11 % (Lewis 2002), making it the leading cause of mortality. The connection 
between menopause and dyslipidemia may play a significant role in the increased incidence 
of CVD observed with increased age in women. Early menopause may place women at 
increased risk for CVD (van der Schouw et al. 1996; Hu et al. 1999). Physical changes, 
including increased fat accumulation and abdominal adiposity, coincident with menopause, 
have been considered part of the biological mechanism by which postmenopausal women 
experience an increase in CVD risk (Matthews et al. 1989). 
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Between the ages of 44 and 65, the percentage of women with serum TC above the 
normal range increases dramatically (Centers for Disease Control and Prevention 1999). In 
addition, a study with perimenopausal women showed significant increases in low density 
lipoprotein cholesterol (LDL-C) and triacylglycerides (TG) and a significant decrease in high 
density lipoprotein cholesterol (HDL-C) within six months of their last menstrual period 
(Jensen et al. 1990). Thus, postmenopausal women are at risk due to a more atherogenic 
lipid profile compared to their menstruating counterparts. 
The dramatic rise in CVD risk in women after menopause can be attributed to the loss 
of endogenous estrogen. Estrogen is known to have a direct effect on the arterial wall; it can 
reverse the vasoconstrictive response of acetylcholine, suggesting the hormone is important 
for vascular smooth muscle response to endothelial-dependent vasodilator capacity 
(Herrington et al. 1994). Estrogen is also associated with a decreased concentration of 
plasma endothelia, a vasoconstrictor (Polderman et al. 1993). Thus, an increase in vascular 
resistance after menopause may be related to estrogen deficiency. The synergistic effect of 
an adverse lipid profile and vascular resistance after menopause may place women at 
increased risk of CVD. 
Racial differences in cardiovascular mortality among women remain largely 
unexplained. African-American women may be at increased risk which may be attributable 
to impaired endothelial function (Loehr et al. 2004). Data from the Third National Health 
and Nutrition Examination Survey, 1988-1994, showed that after accounting for age and 
socioeconomic status, both black and Mexican-American women had a significantly higher 
prevalence of type II diabetes than white women (Sundquist et al. 2001). In addition, black 
women were significantly more likely to have abdominal obesity and hypertension and to be 
physically inactive than white women. 
Modi cable 
The major modifiable risk factors for heart disease in women include dyslipidemia, 
diabetes, hypertension, obesity, cigarette smoking, sedentary lifestyle, and poor nutrition 
(Lewis 2002; Mosca et al. 1997; Kip 2004). Additional atherosclerosis-associated risk 
factors that have more recently been identified include abnormal circulating concentratoins 
of lipoprotein(a), homocysteine, C-reactive protein, serum amyloid A, intercellular adhesion 
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molecule-1, and interleukin-6. (Guyton et al. 1985; Ridker et al. 2000; Kang et al. 1986). 
The relationship between dyslipidemia and CVD will be discussed in more detail in the 
following section. 
The_ influence of diabetes on CVD risk has a greater impact in women than in men 
(Lewis 2002). Diabetic women have athree- to seven-fold higher CVD risk than non-.~--
diabetic women, whereas the risk for diabetic men is two-to three-fold higher than non-
diabetic men. A potential reason for the sex-based difference may be the negative impact 
diabetes has on both lipid markers and blood pressure in women (Manson et al. 1996). 
Hypertension is also a modifiable risk factor; when it is reduced, one's risk of CVD 
also declines. A positive correlation between hypertension and age has been well 
documented, with a prevalence of 4% for young adults, increasing to 65% for 
those >80 years of age (Whelton et al. 1996). Similarly, the correlation of hypertension with 
increased risk of stroke and coronary artery disease has been established. Systolic blood 
pressure and mean arterial pressure were recently reported to be highly correlated to CVD-
related death (van Trijp et al. 2005). A large prospective study including nearly 14,000 
Dutch women, found atwo- to three-fold increase in overall death rate from CVD in 
individuals with systolic blood pressure > 185 mm Hg compared with those whose blood 
pressure was <135 mm Hg (van der Giezen et al. 1990). 
Obesity has been shown to have a positive relationship with CVD risk in women 
(Rich-Edwards et al. 1995). Results from the Nurses' Health Study indicated that after 
adjustments for age and smoking, a mildly to moderately overweight woman has almost 
twice the risk of CVD compared with a lean woman, and that this risk increases to three-fold 
for a woman in the heaviest category (Manson et al. 1990). Some of this risk may be related 
to hypertension, diabetes, and hyperlipidemia, factors that axe often associated with obesity. 
However, it has been reported that moderate weight gain may provide a protective effect 
among very lean postmenopausal women, evidenced by more than a threefold decrease in 
cardiovascular disease mortality risk. It is postulated that the protection might be due to an 
increase in adipose-tissue-derived estrogen production as a result of weight gain (Singh et al. 
2001). 
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The damaging effects of cigarette smoking are well known and well documented. 
-, 
Among middle-aged women, greater than 60% of CVD events are attributable to tobacco 
exposure. The rates of smoking have decreased since the 1960's, but the decrease has been 
slower in women than in men (Rich-Edwards et al. 1995; van der Giezen et al. 1990). 
Prevention of CVD through a "healthy lifestyle"~; appears to have a substantial impact 
on the incidence of CVD in middle-aged and older women. The Nurses' Health Study 
observed that the women who had a good diet, were not overweight, did not smoke, and 
exercised moderately or vigorously for 30 minutes each day, had an 80% lower incidence of 
cardiovascular events than the rest of the population (Stampfer et al. 2000). In addition, the 
study illustrated that improvements in diet and smoking cessation, respectively, accounted 
for a decrease in the incidence of CVD by 16% and 13%. A decrease in one's risk of CVD 
can be accomplished by lowering elevated blood pressure, which is often associated with 
weight reduction, dietary intervention, and reversal of a sedentary lifestyle. An estimated 
60% of men and women in the United States engage in physical activity on a regular basis. 
An increase in physical activity in the general population could greatly affer.t the prevalence 
of CVD. The risk of CVD is estimated to be reduced by as much as 75% in American 
women who exercise regularly compared with those who lead a sedentary lifestyle (Rich-
Edwards et al . 19 9 S) . 
Depression has also been shown to be an independent predictor of CVD in women 
with no history of disease after adjusting for age, race, education, income, diabetes, 
hypertension, smoking, high TC requiring medication, body mass index, and physical 
activity (Wassertheil-Smoller et al. 2004). Also, the relationship between depression and 
CVD might be related to cytokines and will be discussed in more detail in the cytokine 
section of this thesis. Thus, it is important for women and their healthcare providers to 
recognize the symptoms of depression and effectively treat it in an effort to reduce CVD risk. 
Dyslipidemia and other risk factors 
Evidence indicates the severity of atherosclerotic disease of the carotid vessels is 
strongly associated with severity of dyslipidemia, especially increased LDL-C and low HDL-
G concentrations (Wilson et al. 1997). Although elevated concentrations of LDL-C and TG, 
and decreased concentrations of HDL-C, are risk factors for CVD in both men and women, 
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the relative contribution to disease risk development of the lipid profile is sex-dependent. 
Decreased HDL-C and increased TG are independent predictors of CVD risk and stronger in 
women than men (Manolio et al. 1992). Likewise, low HDL-C, after adjusting for age, was 
found to be the most significant predictor of death from CVD in women (Jacobs et al. 1990). 
The Framingham Study, which evaluated HDL-C concentration in women, determined that 
those with <35 mg/dL had a risk of CVD that was eight times greater than women with 
HDL-C >65 mg/dL (Gordon et al. 1977). Improving the serum lipoprotein profile results in a 
decreased risk of cerebral vascular events, such as stroke (Crouse et al. 1997). A meta-
analysis estimated that for every 1 %reduction in TC, there is a 2.5% decrease in the 
incidence of coronary heart disease (Holme 1990). 
Dietary intake, especially source and type of fatty acids, has been well studied in -_-----~ 
relation to reducing CVD risk (Hu et al. 2001). Intake of saturated and trans fatty acids is 
associated with an adverse lipid profile, while intakes of mono- and polyunsaturated fatty 
acids promotes aheart-healthy lipid profile. In addition, a high intake of trans fatty acids 
adversely affects endothelial function (Lopez-Garcia et al. 2005) and has been associated 
with biomarkers of systemic inflammation (Mozaffarian et al. 2004). 
Not only is an undesirable lipid profile important in atherosclerotic CVD risk, but 
damage to LDL particles may also be an important factor. The oxidation of LDL plays a 
central role in the pathogenesis of atherosclerosis. The oxidation of LDL initiates a cascade 
of events including: accelerated platelet aggregation; injury to arterial endothelial cells; and 
production of cytokines, adhesion factors, growth factors, and other substances that facilitate 
development of foam cells and fatty streaks, eventually leading to atherosclerosis. 
Atherosclerosis is characterized by a thickening of the arterial wall due to smooth muscle cell 
proliferation, lipid deposits, and fibrosis. Subsequent rupture of the lipid-containing plaques 
results in thrombosis and leads to myocardial infarction and stroke. 
Oxidative Stress 
Oxidative stress is an imbalance between the production of reactive species and the 
body's natural protective mechanisms to cope with these reactive compounds and prevent 
adverse effects (Mayne 2003). Oxidative stress can arise from many sources including 
cellular respiration, exercise, and the normal aging process. Oxidative stress has been 
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suggested to be involved in the aging process etiology of diseases including cancer, CVD, 
and cataracts (Institute of Medicine 2000). An illustration of free radical damage to various 
targets is shown in Figure 2. 
Figure 2. Free Radical Damage 
Target Consequence 
Proteins Increased turnover 
Lipid oxidation 
DNA 
Decreased enzyme activity 
Membrane damage 
LDL damage 
 ► Mutation 
Cell injury 
~ .CVD 
►Cancer 
Most oxygen is used in cellular metabolism which mainly occurs in the mitochondria 
and is related to energy metabolism. Cellular enzymes and controlled metabolic processes 
normally keep oxidative damage to a minimum. However, at times of increased oxidative 
stress, including high metabolic demands and external factors such as sunlight, smoking, and 
pollution, body defense mechanisms may not be adequate and oxidative damage may occur 
due to the generation of free radicals. Free radicals are atoms or molecules with unpaired 
electrons, such as superoxide anion, peroxyl radical, and hydroxyl radical. Many radicals are 
highly reactive and can either donate an electron to or accept an electron from other 
molecules. Thus, these molecules are generally short-lived and may react with 
macromolecules such as proteins, lipids, and nucleic acids (Young and Woodside 2001). 
Other reactive molecules, such as molecular oxygen, singlet oxygen, and hydrogen peroxide, 
are not free radicals per se, but are capable of initiating oxidative reactions and subsequently 
generating free-radical species. Together, free radicals and reactive oxygen molecules are 
called reactive oxygen species (ROS). Excessive production of ROS may be related to a 
variety of neurodegenerative and other chronic diseases. An accumulation of ROS may lead 
to increased activation of polymorphonuclear leukocytes during infection or be influenced by 
the pro-oxidant effect of tumor necrosis factor-a (TNF-a), produced by activated 
macrophages (Das et al. 1990). 
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RO S can attack cellular membrane lipids, nucleic acids, proteins, and enzymes 
resulting in cellular damage and cellular degeneration. Specifically, ROS attack double 
bonds in polyunsaturated fatty acids, inducing lipid peroxidation (shown in Figure 3 ), 
causing cellular oxidative damage. For example, oxLDL has been shown to be involved with 
the pathogenesis of CVD, while oxidatively modified DNA may play a role in carcinogenesis 
(Poulsen et al. 1998). In addition, cataracts are a result of oxidation of proteins, which 
aggregate and accumulate in the lens of the eye (Taylor 1993). 
The following reactions illustrate the steps implicated in lipid peroxidation, consisting 
of three steps: initiation, propagation, and termination. 
Figure 3. Lipid Peroxidation (Esterbauer 1995) 
LH + X' ~ L' + XH (Initiation) 
L' + OZ —> LOO' (Lipid Peroxy Radical Formation) 
LOO' + LH ~ LOOH + L' (Chain Propagation) 
LOO' + AOH ~ LOOH + AO' (Antioxidant Scavenging) 
LOO' + LOO' ~ non-radical product + OZ (Termination) 
Lipid peroxidation is the process whereby free radicals accept electrons from the 
lipids in cell membranes, resulting in cell damage. Initiation is the step whereby a fatty acid 
radical is produced. The fatty acid radical is not a stable molecule so it reacts readily with 
molecular oxygen, thereby creating a Peroxy-fatty acid radical, which is also unstable. It 
may then react with another free fatty acid, producing a different fatty acid radical and a 
hydrogen peroxide. Free radicals react by producing radicals, causing chain propagation. 
LDL resistance to oxidation may depend upon adequate dietary antioxidant status, including 
a-tocopherol, ~3-carotene, and selenium. 
Various markers of oxidative damage in lipids can be measured in vivo including: 
oxidized LDL, LDL resistance to oxidation, breath hydrocarbons, thiobarbituric acid-reactive 
substances, and F2 isoprostanes (Mayne 2003). F2 isoprostanes are produced from free-
radical-induced peroxidation of arachidonic acid, formed in phospholipids, cleaved, and 
released into circulation before excretion in the urine as free isoprostanes (Roberts and 
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Morrow 1997). Urine is better than serum to quantify isoprostanes because some factors are 
shown to affect serum concentrations. For example, aspirin suppresses the most abundant F2
isoprostane, 8-isoprostaglandin Fla, in the serum but not in urine (Reilly et al. 1996). Also, 
urine may be stored for a longer period of time than serum without isoprostanes degrading. 
Elevated markers of protein oxidation have also been shown to be associated with 
diseases such as: Alzheimer's disease, Parkinson's disease, muscular dystrophy, 
amyotrophic lateral sclerosis, and rheumatoid arthritis (Stadtman et al. 1998). Oxidatively 
modified proteins are not repaired and must be removed by proteolytic degradation (Levine 
et al. 1990). A decrease in efficiency of proteolysis causes an increase in the cellular content 
of oxidatively modified proteins. The concentration of these modified molecules can be 
quantified by measurement of the protein carbonyl content. Accumulation of modified 
proteins disrupts cellular function either by loss of catalytic and structural integrity or by 
interruption of regulatory pathways (Stadtman and Levine, 2000). In addition to 
cataractogenesis (Garland 1990), exercise-induced oxidative stress in muscle may be related 
to elevated protein oxidation (Witt et al. 1992). 
Biomarkers of DNA oxidation include 8-hydroxy-2' -deoxyguanosine (8-OHdG), 
antibodies to oxidized DNA, and the Comet assay which detects DNA strand breaks. Of the 
three available methods, 8-OHdG is the most commonly used marker for DNA damage. This 
method is based on a common oxidative event in DNA, oxidation of the C-8 of guanine, 
which ultimately results in a mutagenic lesion that produces a G-to-T transversion mutation 
(Mayne 2003). 
The antioxidant defense system is composed of enzymatic and nonenzymatic 
substances, or dietary antioxidants. An antioxidant is any substance that significantly delays 
or inhibits the oxidation of a substrate (Halliwell and Gutteridge 1995). Thus, the 
physiological role of antioxidants is to prevent damage to cellular components arising as a 
consequence of chemical reactions involving free radicals. Oxidative damage may be 
prevented by a normal antioxidant defense system that scavenges ROS. The body's 
antioxidant defenses depend upon 1) the integrity of the enzymatic system which requires an 
adequate intake of trace minerals such as iron, selenium, copper, zinc, and manganese and 2) 
adequate concentrations of vitamins A, C, E, and ~-carotene in the cytoplasm and lipid 
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membrane of the cells that are derived from dietary sources (Allard et al. 1998). Many 
dietary constituents may scavenge free radicals and have direct antioxidant activity, such as 
flavonoids, or indirect antioxidant activity, such as zinc and selenium, trace minerals that are 
necessary for antioxidant enzymes. 
Figure 4. Oxidative Stress 
Environmental Factors 
,:::: 
~ Oxidative 
~+ Burst 
Age 
Cellular 
Respiration 
DIdA Damage 
SOD 
(Cu & Zn) H2O2 
Fee+
1 
Protein Damage 
CAT 
(Fe} 
GPX 
(Se) 
H2O + 02 
H2O 
Lipid Peroxidation 
Intracellular antioxidant enzymes include superoxide dismutase (SOD), catalase 
(CAT), and glutathione perioxidase (GPX). Erythrocyte SOD catalyzes the dismutation of 
superoxide anions to hydrogen peroxide and oxygen, while CAT catalyzes the conversion of 
hydrogen peroxide to water and oxygen. Additionally, GPX has direct radical-scavenging 
activity and may represent glutathione activity in other tissues (Meister et al. 1979), and 
appears to be sensitive to body selenium stores (Cohen et al. 1985). Figure 4 illustrates 
oxidative status, including antioxidant enzymes and free radical damage. 
Antioxidant effects are of interest because of their ability to protect against oxidative 
damage, which is linked to the development of atherosclerotic CVD and cancer. For 
instance, oxidative DNA damage is high in women who have first-degree relatives with 
breast cancer (Djuric et al. 1998) and in patients with invasive ductal carcinoma (Malin et al 
1993). Breast cancer patients were also shown to have increased ROS production and lipid 
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peroxidation (Ray et al. 2000; Kumaraguruparan et al. 2002). Interestingly, studies in both 
animals and humans have shown a potentially important antioxidant role for both 
endogenous and exogenous estrogens (Yagi 1997; Nathan and Chaudhuri 1998). This 
observation supports the hypothesis that postmenopausal women are at increased risk for 
oxidative stress due to loss of endogenous estrogen production. In American women, age, 
markers of glucose metabolism, irnsulin resistance, and postmenopausal status have been 
associated with increased oxidative stress and reduced antioxidant potential (Trevisan et al. 
2001). While it is generally accepted that insulin resistance may play a role in contributing 
to oxidative stress, it has been suggested that oxidative stress may result in insulin resistance 
(Laville et al. 1995). In addition, endothelial dysfunction and increased vascular oxidative 
stress predict the risk of cardiovascular events in patients with coronary heart disease 
(Heitzer et al. 2001). It has also been shown that obesity increases with oxidative stress 
which may trigger the development of insulin resistance (Urakawa et al. 2003). Adipose 
tissue is highly metabolic and abdominal fat is involved in the production of oxidative stress. 
A large waist circumference is associated with a high concentration of oxLDL independently 
of BMI in both men and women (Weinbrenner et al. 2006). 
Dietary antioxidants protect the body against oxidative stress either by directly 
reacting with or quenching free radicals directly, or by indirectly decreasing the damage 
caused by the free radicals. R-carotene is afat-soluble carotenoid and antioxidant that 
concentrates in lipoprotein fractions, such as HDL and LDL, and accumulates in 
atherosclerotic plaques (Stahl and 5ies 1997). High serum ~3-carotene concentration has been 
shown to protect endothelial tissue from damage by decreasing cholesterol uptake into those 
cells and may inhibit the formation of atherosclerotic lesions (Boring and Hennekens 1997; 
Vogel et al. 1997). An increase in lipid peroxidation has also been associated with lower 
plasma concentrations of antioxidants such as vitamin C, a-tocopherol, (3-carotene, and 
selenium (Allard et al. 1998). 
Lycopene is a carotenoid present in tomato products and has been shown to have the 
highest antioxidant capacity of the carotenoids by quenching singlet oxygen and trapping 
peroxyl radicals (Di Mascio et al. 1989; Miller et al. 1996). It has also been reported that 
high consumption of tomato products improves plasma antioxidant status, lowers lipid 
14 
peroxidation (Parfitt et al. 1994), and improves the antioxidant defense of LDL against attack 
by singlet oxygen (Oshima et al. 1996). Furthermore, the consumption of tomato products 
has also been shown to reduce the susceptibility of lymphocyte DNA to oxidative damage 
(Riso et al. 1999). More recently, the combination of the carotenoids, lutein, (3-carotene, and 
lycopene, at a dose achievable through the diet (12 mg total or 4 mg of each), has been 
shown to exert protection against oxidative DNA damage (Zhao et al. 2006). 
It is well known that a higher intake of omega-3 fatty acids from fish or plant sources 
lower the risk of CVD (Hu and Willet 2002). Omega-3 fatty acids reduce CVD risk by 
reducing TG, decreasing platelet aggregability, and exerting antiarrhythmic effects (Conner 
2000). In normotriglyceridemic and hypertriglyceridemic individuals fish oil 
supplementation has been shown to stimulate omega-3 fatty acid incorporation into 
erythrocyte membranes (Mabile et al. 2001). Likewise, a-lipolic acid has been shown to be 
protective against oxidative stress-induced endothelial function (Park et al. 2004). a-Lipolic 
acid is a thiol antioxidant with direct free-radical scavenging potential (Packer et al. 1995, 
1997) and exhibits beneficial effects on vascular and endothelial function (Evans et al. 2002; 
Visioli et al. 2002). 
Iron Status 
Iron is an essential nutrient needed by humans for normal redox reactions that occur 
under tightly controlled conditions. As a part of the protein hemoglobin, iron is essential to 
transport oxygen and carbon dioxide to and from tissues. Iron is needed in the electron 
transport system to provide energy to the cell. In addition, iron is necessary for cell 
proliferation, DNA synthesis, brain, and immune function (Corti et al. 1997). On average, 
one third of total body iron is bound to the storage protein ferritin primarily found in the 
liver, spleen, and bone marrow. The other two thirds of body iron facilitates metabolic or 
enzymatic function, and is transported by transferrin. Iron-containing enzymes catalyze the 
transfer of electrons and oxidation-reduction reactions (Swanson 2003). Hence, it is the 
biological property of iron to exist in two oxidation states [(ferric (Fe3+) and ferrous (Fe2+)], 
which may pose a threat when not properly modulated by iron-binding proteins or 
antioxidants. 
15 
During adulthood, iron stores gradually increase in men; in women, iron stores begin 
to increase after menopause as a result of the cessation of menstruation. Data from the Third 
National Health and Nutrition Examination Survey report the mean serum ferritin 
concentration in premenopausal women, postmenopausal women, and men of 3 3.6, 93.4, and 
139.9 µg/1, respectively. Serum ferritin has been shown to be higher in postmenopausal 
women compared to premenopausal women, both in blood donors (43.4 vs. 23.1 µg/L, 
P<0.001) and in nondonors (71.7 vs. 32.8 µg/L, P<0.001) (Berge et al. 1994). Since iron 
stores, TC, and LDL-C increase with age, it is not surprising that iron stores and blood lipids 
are positively associated. Serum ferritin has been shown to be positively associated with TC 
and LDL-C, after adjusting for age (Berge et al. 1994). Whether there is any relationship 
between iron and estrogen or hormone therapy remains unclear. There is evidence that 
women using hormone therapy have better iron status parameters and lipid profiles than 
women not on hormone therapy (Penckofer et al. 2000). It has also been shown that 
postmenopausal women have higher TC, LDL-C, and TG compared to premenopausal. 
women with similar diet, body weight, and body fat distribution (Masse et al. 2004). 
Epidemiological studies suggest a positive relationship between body iron stores and 
risk for CVD (Salonen et al. 1992; Danesh et al. 1999). However, some reports suggest that 
there is not enough evidence to link iron status consistently with CVD in epidemiological 
studies (Corti et al. 1997). Since aspirin is associated with reduced risk of myocardial 
infarction and lowered iron stores, this suggests a role for iron in CVD. The Framingham 
Heart Study illustrated aspirin of serum ferritin lowering effect of aspirin, which may be 
related to findings from epidemiologic studies regarding associations between elevated serum 
ferritin and heart disease risk (Fleming et al. 2001). Furthermore, in the presence of other 
risk factors, serum ferritin may adversely affect ischemic heart disease risk in the elderly 
(Klipstein-Grobusch et al. 1999). 
A decrease in body iron stores has been shown to be cardioprotective due to a 
reduction of iron availability which impairs nitric oxide action, thereby improving 
endothelial function in patients with CVD (Duffy et al. 2001). Transition metals, such as 
iron and copper, catalyze free radical oxidation of lipids and proteins. Iron may contribute to 
atherosclerosis by promoting oxidative modification of LDL (or oxLDL), a key step that 
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leads to scarring and inflammation of arteries. In vitro, free iron participates in the Fenton 
and Haber-Weiss reactions, reducing hydrogen peroxide to the harmful hydroxyl radical, as 
shown in the Figure 5. 
Figure 5. Fenton and Haber-Weiss Reactions 
Fenton reaction (Emerit et al. 2001) 
Fe3+ + ®2• - —~ Fe2+ + 02
Fe2+ + H2O2 —~Fe3+ + HO- + HO• 
Haber-Weiss reaction (Haber and Weiss, 1934) 
02-• + H2o2 -~ 02 + Ho- + Ho• 
Unbound iron catalyzes the reaction of the superoxide radical and hydrogen peroxide 
to form the hydroxyl radical. The highly reactive hydroxyl radical is capable of binding a 
hydrogen atom from polyunsaturated fatty acids, which initiates lipid peroxidation. In 
addition, once lipid hydroperoxides accumulate, free iron may directly initiate additional 
lipid peroxidation. However, in healthy individuals, iron is tightly bound to transferrin in 
circulation. Thus, only a small amount of catalytic iron is typically found in the body under 
normal physiological conditions (Reddy and Clark 2004). Any released iron is immediately 
chelated in cells by low molecular weight compounds, such as citrate or adenosine 
diphosphate (Emerit et al. 2001). 
The hypothesis that transition metals accumulate in human arteries remains 
unconfirmed. Elevated concentrations of iron and copper were shown in the intima of 
atherosclerotic lesions compared to healthy controls, which supports the hypothesis that iron 
may accumulate and contribute to atherogenesis. Women, with and without carotid plaques, 
had average serum ferritin of 90.8 and 67.3 µg/L (P<0.001), respectively, whereas men, with 
and without plaques, had average serum ferritin of 163 and 147 µg/L (P<0.31), respectively. 
In the same study, adose-response relationship between serum ferritin and carotid 
atherosclerosis was implicated in that a higher ferritin concentration was positively 
associated with a greater odds ratio for carotid plaque prevalence in both men and women 
(Wolff et al. 2004). 
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The brain may be especially vulnerable to oxidative stress and neurological damage 
due to high amounts of polyunsaturated fatty acids in membrane lipids, iron, and low 
concentrations of antioxidant enzymes. Acase-cohort study of stroke patients matched with 
a random sample from the European Prospective Investigation Into Cancer and Nutrition 
measured serum ferritin, serum iron, and transferrin saturation (van der et al. 2005). Serum 
ferritin concentration ranged from 4.6 to 115 8.0 µg/L, and the overall median concentration 
was 103.0 µg/L. Of the 1,132 women in the study, 1.9% had serum ferritin concentration 
< 15 µg/L and 4.3 %had >3 00 µg/L. The study showed that the highest tertile of serum 
ferritin concentration was associated with an increased risk of ischemic stroke compared to 
the lowest tertile. A mechanism explaining the observation between high ferritin and stroke 
could be attributed to the catalytic properties of iron in the production of hydroxyl radicals. 
In a different study, zinc antagonized the effect of iron in atherosclerotic lesions when free 
radicals were produced by iron, suggesting zinc and iron have opposite roles (Mingin et al. 
2003 ). In the Iowa Women's Health Study, researchers found that a higher intake of heme 
iron may be harmful, while a high intake of zinc may be beneficial in relation to CVD 
mortality in the presence of a trigger, such as alcohol disturbed homeostasis (Lee et a1. 2005). 
A recent study using mice confirmed in vivo results showing an increase in vascular 
deposition accompanying superoxide release with ahigh-fat and iron-supplemented diet (~ao 
et al. 2005). Fatty acids might mediate iron intracellular translocation and subsequent 
oxidative injury. An in vitro study showed that palmitic acid facilitated iron translocation 
into cells and mitochondria through a transferrin receptor-independent mechanism, resulting 
in intracellular iron overload and subsequent ROS overproduction and lipid oxidation. 
Results from the Bruneck Study, after adjusting for major vascular risk factors, revealed that 
serum ferritin was one of the strongest indicators of carotid artery disease in both rnen and 
women. In addition, the predictive significance of ferritin was found to be synergistic with 
hypercholesterolemia (Kiechl et al. 1994). Therefore, the relationship between body iron 
stores and blood lipids seems be interrelated with regards to increased CVD risk. 
However, some studies disagree with the hypothesis that excess body iron is 
associated with CVI~ risk. Eichner et al. (1998) found no relationship between increased iron 
stores in atherosclerosis patients. Likewise, in a rat model, serum iron was found to have no 
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effect on serum lipids or blood pressure; however, rats have distinct differences in lipid and 
plasma lipoprotein metabolism (no hepatic lipase or a protein similar to apolipoprotein-AII) 
compared to humans (Turbino-Ribeiro et al. 2003). Iron supplementation did not increase 
the susceptibility of LDL to oxidative modification in women with low iron status (Binkoski 
et al. 2004). In addition, three controlled feeding studies found no relationship between iron 
status and LDL oxidative susceptibility (Derstine et al. 2003). Lastly, Sempos et al. (2001) 
found no evidence that elevated iron stores is directly related to CVD. Therefore, in a 
healthy population, iron excess is not a major concern; however, in persons with 
hyperlipidemia, elevated oxidative stress may place individuals at greater risk for CVD 
(Reddy and Clark, 2004). 
There has been less research on the relationship between body iron stores and body 
fat distribution, despite the association of each factor with CVD risk. In Mexican-American 
men, serum ferritin concentration was negatively associated with waist-to-hip ratio (WHR) 
and other indices of body fat distribution and obesity (Gillum 2001). It is important to note 
that waist and hip circumferences assess different aspects of body composition and fat 
distribution and may have independent and opposite effects on CVD risk factors. For 
example, a narrow waist and large hips may both be protective against CVD, hence the WHR 
is a crude index for determining disease risk (Seidell et al. 2001). In addition, there may be 
ethnic or cultural differences in the association between iron stores and body fat distribution. 
Chambers et al. (2006) found that serum iron was inversely correlated with BMI, waist 
circumference, and fat mass among Hispanic women but not among African-American, 
white, or Asian women. 
Serum ferritin concentration was also related to the degree of insulin resistance in 
Chinese women, but not in men, after adjusting for age, BMI, and menopausal status (Sheu et 
al. 2003). More recently, a study reported a direct association between serum ferritin and 
visceral fat area and subcutaneous fat area using computed tomography. These results 
suggest that serum ferritin may be a useful indicator of systemic fat content and degree of 
insulin resistance (Iwasaki et al. 2005). A possible mechanism explaining this relationship 
could be that increased iron stores in the liver may induce liver-mediated insulin resistance 
and reduce the ability of insulin to suppress hepatic glucose production (Fernandez-Real et 
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al. 1998). Ferritin is associated with decreased insulin sensitivity and increased fasting 
plasma insulin and glucose, abnormalities which may lead to increased adiposity (Gillum 
2001). Lastly, iron stores in muscle might enhance the oxidation of free fatty acids, which in 
turn might interfere with glucose disposal. Elevated free fatty acids can damage pancreatic 
beta cells and cause insulin resistance (Tuomainen et al. 1997). Nonetheless, the direct 
association of serum ferritin to central adiposity warrants further investigation. 
Homocysteine 
Homocysteine (Hcy) is a sulfer-containing amino acid that is an intermediary product 
in methionine metabolism. Deficiencies in vitamin cofactors in the Hcy pathway, including 
folate, pyridoxine, and cobalamin may also lead to hyperhomocysteinemia. Individuals with 
increased plasma Hcy are likely to have inadequate concentrations of one or more of these 
vitamins (Selhub et al. 1993, Robinson et al. 1995). In patients with an inborn error of Hcy 
metabolism (homocysteinuria), due to a deficiency of an enzyme involved in the Hcy 
pathway, lowering the elevated circulating Hcy concentrations greatly reduces CVD risk 
(Wilcken and Wilcken 1997; 1998). 
Hyperhomocysteinemia hcs evolved from a rare condition predisposing individuals to 
atherothrombosis to a common disorder of atherosclerosis in the general population. The 
pathogenesis of atherothrombotic vascular disease may be closely associated with 
hyperhomocysteinemia in relation to oxidative stress, vitamin deficiencies, and endothelial 
dysfunction (Loscalzo 1996). Increased circulating Hcy is a contributing factor to the 
development of premature atherosclerosis and an independent risk factor for stroke and 
myocardial infarction (Stampher et al. 1992). Moderate hyperhomocysteinemia, defined as 
plasma concentrations of Hcy > 15-16 µmol/L, has been identified in 20-40% of patients 
with atherosclerotic vascular disease (Duell and Malinow 1998). 
In healthy, postmenopausal US women, increased concentration of Hcy is correlated 
with increased ri sk of future CVD (Ridker et al. 1999). Estradiol has been shown to have 
abeneficial effect on preserving the endothelial integrity and function in a condition of Hcy-
induced oxidative stress (Dimitrova et al. 2002). In a prospective cohort, the Hordaland 
Homocysteine Study of almost 5000 Norwegian men and women, plasma Hcy was a strong 
predictor of both cardiovascular and noncardiovascular mortality in individuals 65-72 year of 
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age (Vollset et al. 2001). This study supports results from elderly Framingham subjects 
(Bostom et a1. 1999) and from a study of Jerusalem men and women (Kark et al. 1999). 
Plasma Hcy concentration was significantly correlated with the proinflammatory cytokines 
interleukin-1 receptor antagonist and interleukin-6 (IL-6) in Italians over 65 years of age 
(Cori et al. 2005), contributing to the association between Hcy and atherosclerosis. In 
addition, the following factors were significant independent correlates with Hcy: a sedentary 
state; intakes of vitamin B-6, B-12, and folic acid; serum folate; and serum a-tocopherol. 
Graham et al. (1997) detected hyperhomocysteinemia in 42% of patients with 
cerebrovascular disease, 28% with peripheral vascular disease, and 30% with coronary 
vascular disease. In addition, with an increase of 5 µmol/L in Hcy concentration, the relative 
risk of CVD has been estimated to increase by approximately 60% for men and 80% for 
women (Graham et al. 1997). Interestingly, women may be able to control their Hcy 
concentration by decreasing coffee and alcohol consumption, whereas men should focus on 
increasing physical activity, dietary fiber, and dietary folate (Mennen et al. 2002), indicating 
a difference in Hcy metabolism between the two sexes. 
Studies have shown that elevated Hcy concentration is associated with premature 
vascular disorders, including myocardioal infarction and cerebral and vascular diseases 
(Malinow et a1. 1993; Clarke et al. 1991). Ameta-analysis showed that increasing Hcy 
concentrations has a graded effect on CVD risk, meaning the greater the Hcy concentration, 
the greater risk of CVD will result (Boushey et al. 1995). Jang et al. (2001) revealed that 
male CVD patients had greater visceral fat accumulation, higher insulin and Hcy 
concentrations, and lower insulin-like growth factor I, superoxide dismutase, and ~3-carotene 
concentrations than healthy men matched for age and BMI. III addition, CVD patients with 
diabetes had the greatest visceral fat and Hcy concentration acid the lowest HDL-C and 
carotenoid concentrations. 
It is proposed that Hcy may have direct cytotoxic effects, producing free radicals that 
may cause endothelial damage and dysfunction (Currie et al. :1996). High circulating Hcy 
concentration may promote oxidative damage because the sulfhydryl group of Hcy acts 
catalytically with ferric or cupric ions to generate hydrogen peroxide, oxygen, and 
homocysteinyl radicals (Olszewski and McCully 1993). Thus, a high Hcy concentration has 
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been associated with low antioxidant capacity (Buczynski et al. 1993). Oxidative stress is 
increased by Hcy via stimulating superoxide production (McDowell and Lang 2000). This 
relationship was supported by a study (Jang et al. 2001) where patients with or without 
diabetes had lower superoxide dismutase activity than did control subjects. 
Folic acid, or folate, is a micronutrient found in green leafy vegetables, some animal 
products, and fortified enriched grain products in the United States to prevent neural tube 
defects in newborns. Folate is needed to provide one-carbon units for more than 100 
biochemical processes, including Hcy metabolism and deoxynucleotide synthesis. Increasing 
evidence shows that folate may contribute to CVD prevention via reducing plasma Hcy 
concentration by remethylating Hcy to methionine (Haynes 1999). Chait et al. (1499) 
demonstrated that a prepared meal plan providing > 100% of the recommended dietary 
allowances (RDA) for 23 micronutrients, including folate, resulted in increased intakes and 
serum concentrations of folate and vitamin B-12 and were associated with reduced serum 
Hcy concentration in individuals at increased CVD risk. The current RDA of 180 µg/d may 
not be sufficient to maintain a low plasma Hcy concentration in some postmenopausal 
women (Jacob et al. 1998). Increased lipid peroxidation during folate deficiency may be a 
consequence of increased Hcy concentration. Folic acid may provide a beneficial effect on 
the vascular endothelium by reducing plasma Hcy or by reducing oxidative stress (Wilmink 
et al. 2000). An increase in oxidative stress may play a role in reducing endothelial nitric 
oxide activity in hyperhomocysteinemic patients (Faraci, 2003). However, a study has 
shown that folic acid administration improved endothelial function without any effects on 
Hcy concentration (Verhaar et al. 1998). In addition, folic acid was shown to have 
antioxidant properties and direct scavenging effects in vitro and may directly improve nitric-
oxide production by enhancing enzymatic activity of nitric-oxide synthase (Stroes et al. 
2000). 
Cytokines 
Recent evidence has suggested that CVD is an inflammatory disease mediated by 
systemic inflammatory markers. The precise triggering of the inflammatory response is 
unknown. However, activated neutrophils, lymphocytes, monocytes, and increased 
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proinflammatory cytokines, such as IL-6, CRP, and TNF- a are involved in the 
pathophysiology of CVD (Meng et al. 2006). 
IL-6 may play an important regulatory role in the development of atherosclerosis by 
metabolic, endothelial, and coagulation mechanisms. IL-6 increases glucose uptake, 
increases the release of adhesion molecules by the endothelium, increases the hepatic release 
of fibrinogen, and exerts procoagulant effects on platelets (Yudkin et al. 1999). Cytokines 
have also been associated with components of insulin resistance syndrome, including insulin 
SenSltivlty, high TG and low HDL-C concentrations, and elevated blood pressure (Dan et al. 
1995). In addition, IL-6 and TNF-a inhibit lipoprotein lipase and stimulate lipolysis. 
Endothelial expression of other chemokines and adhesion molecules, induced by IL-6, may 
affect TG metabolism by altering endothelial generation of nitric oxide following elevated 
non-esterified fatty acid concentration (Samad et al. 1996). Lastly, a procoagulant state may 
be attributed to the effect of IL-6 on platelets, fibrinogen concentration, and coagulation, and 
to the effect of TNF-a on plasminogen activator inhibitor by hepatocytes, endothelial cells, 
and adipose tissue (Mohamed-Ali et al. 1997). Therefore, IL-6 plays a role in the 
progression and etiology of CVD. 
In a study of healthy men and women, the synthesis and circulating concentration of 
IL-6 increase with adiposity. It is estimated that one third of circulating IL-6 originates from 
the adipocyte. In vitro data suggest a greater contribution of IL-6 and TNF-a from visceral 
fat than from subcutaneous fat (Mohamed-Ali V et al. 1997), which supports the idea that 
adipose tissue around the organs is more atherogenic than fat directly under the skin. Hence, 
obesity can be regarded as a low-grade inflammatory condition in which IL-6 is synthesized 
from adipose tissue. 
Interestingly, it has also been well-documented that psychological factors, such as 
stress, can elevate IL-6 concentration influenced of catecholamines. The hypothalamo-
pituitary-adrenal axis may be stimulated by IL-6, thereby increasing corticotrophin releasing 
hormone, adrenocorticotrophic hormone, and cortisol. Patients with melancholic depression 
patients were shown to have elevated IL-6 along with other CHID risk factors including: 
central adiposity, increased blood :pressure, insulin resistance, hypertriglyceridemia, and low 
LDL-C (Chrousos and Gold 1998). Psychosocial stress may elevate IL-6 concentration, 
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thereby stimulating the hypothalamo-pituitary-adrenal axis, resulting in increased abdominal 
fat storage, insulin resistance, and dyslipidemia (Brunner et al. 1997). 
Inflammation has also beE;n reported to be increased in type 2 diabetics. Women with 
type 2 diabetes and CVD have a significantly greater IL-6 concentration compared to age-
matched controls, suggesting an ~~dditive effect of the two diseases on inflammation (Tuttle et 
al. 2004). IL-6 elevation was sho►wn to be proportional to insulin resistance and blood 
glucose (Bastard et al. 2000). Wl1en obese patients were placed on energy-restricted diets for 
three weeks, IL-6 significantly dE;creased and IL-6 and TNF-a were shown to be positively 
correlated with BMI. Hence, IL-~6 may reflect amount of adipose tissue and degree of insulin 
resistance. In a study with 108 postmenopausal women, the women with a combination of 
high visceral adipose tissue and high insulin resistance were characterized as having a greater 
deterioration in metabolic risk profile than women with one of the two conditions (Piche et 
al. 2005). 
The relationship between cytokines and hormone status has been studied in 
postmenopausal women who are at increased risk of CVD. Postmenopausal women on 
hormone therapy were shown to lhave elevated CRP, while no relation was found between 
IL-6 and CRP (La.koski and Herrington 2005). However, Vitale et al. (2005) found plasma 
IL-6 to be a stronger predictor of adverse cardiovascular events than CRP and that CRP was 
associated with an adverse event only when IL-6 was also elevated. Thus, menopause and 
estrogen status have a variety of effects on inflammatory markers and hormone therapy may 
modulate the relationship between obesity and inflammatory cytokine production. The 
Women's Health Initiative study found a significant relationship between of CRP, but not IL-
6, and use of hormone therapy (L,anger et al. 2005). This evidence suggests CRP is 
influenced by factors other than l:L-6, possibly a component of hormone therapy. Further 
studies are needed to determine the relationship between estrogen status, cytokines, CVD risk 
in postmenopausal women. 
Prevention 
Hormone and Estrogen Therapi~E~s 
Although CVD has often been regarded as a disease impacting men, after menopause 
the risk is more similar in both ~;~enders. Premenopausal women are relatively protected from 
24 
CVD compared to postmenopausal women attributed to the female sex hormone, estrogen. 
The difference in mortality relate-c~ to CVD between pre- and postmenopausal women 
suggests that premenopausal worYlen have endothelial protective factors that are lost after 
menopause. The site of estrogen action is not only reproductive tissues, but also the bone, 
liver, brain, and vasculature. Bo,~t:h genomic, mediated by estrogen receptor alpha and beta, 
and nongenomic mechanisms, through nitric oxide, do not explain the effects of estrogen on 
preserving the vasculature under conditions of oxidative stress (Dimitrova et al. 2002). In 
vitro and in vivo studies show th,~lt estrogen prevents vascular injury in conditions of induced 
hyperhomocysteinemia and decrf~ases Hcy in animals on a hyperhomocysteinemic diet 
(Dimitrova et a1. 2001 a and Dimitrova et al. 2001 b). In addition, estrogen was found to have 
antioxidant properties by enhancing glutathione, leading to a reduction in hydrogen peroxide 
concentration (caused by high H~~y), resulting in reduced of endothelial damage (Dimitrova 
et ai 2001). Hence, estradiol mazy have a beneficial effect on preserving the endothelial 
integrity and function in conditic~~ls of Hcy-induced oxidative stress. 
Due to a loss of estrogen in the postmenopausal years, some women consider taking 
hormone therapy to improve their lipid profile, risk of osteoporosis, and memory, mood, and 
hot flushes. However, there have been reports that the risks of hormone therapy outweigh 
the benefits and can lead to fatal cardiovascular events and breast and uterine cancers 
(Writing Group for the Women's Health Initiative Investigators 2002, Manson et al. 2003). 
In the Women's Health Initiative- Study, estrogen alone was shown to have no effect on 
coronary heart disease risk but did increase the risk for stroke and deep vein thrombosis. 
Investigators recommend that es~~~rogen alone should not be used to prevent chronic disease 
and should only be used at the srr~allest effective dose for the shortest amount of time to treat 
menopausal symptoms, especially for women less than 60 years of age (Writing Group for 
the Women's Health Initiative Investigators 2004). Whether hormone therapy protects 
women from CVD via reducing :Kcy, iron stores, and oxidative damage needs further 
investigation. 
Physical Activity 
It is estimated that 66% c►:f Americans are overweight and 3 3 %are considered 
clinically obese, defined as having a BMI > 30 kg/m2 (Flegal et al. 2002). Thus, it is crucial 
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for men and especially postmeno~~ausal women to focus attention on a healthy diet and 
exercise to help combat CVD ris:k~. Epidemiologic evidence clearly shows that physical 
activity is an important modifiable risk factor for CVD (Hoyert et al. 2001; Pate et al. 1995) 
and consistently reduces morbidil:y and mortality from CVD (Kohl 2001; Wannamethee and 
Shaper 2001). Ameta-analysis of 3 0 studies using female subjects quantified the 
relationship of physical activity in healthy women to CVD outcomes and assessed the effect 
of minimal amounts of physical ~~ctivity to reduce CVD risk. The conclusion was 
encouraging; inactive women co~~11d benefit slightly by increasing their physical activity 
level, to walking one hour per week (Oguma et al. 2004). Excess body weight and physical 
inactivity are associated with higher TG, TC, and LDL-C, and lower HDL-C (Brown et al. 
2000). One reason for higher HD►L-C in physically active individuals is due to the increased 
formation of HDL-C from apolip~~protein A-I and cellular lipids (0lchawa et al. 2004). 
Physical activity is effective in lowering TGs in particular and TC in general. In addition, 
physical training increases insulin sensitivity (Hardin et al. 1995) and lowers blood pressure 
(Blair et al. 1989). Therefore, pri;ysical activity is crucial to prevent chronic disease by 
maintaining a healthy weight and by maintaining normal concentrations of circulating lipids. 
Physical activity also improves i~~~mune response and overall optimal health. 
In contrast, aerobic exercise increases oxygen consumption and free radical formation 
(Brownell and Bachorik 1982), t]h~ereby consuming circulating antioxidants (Davies et al. 
1982) and increasing the rate of lipid peroxidation and oxidation of LDL particles (Berg et al. 
1994; Sanchez-Quesada et al. 19'~~5). In addition, relatively intense aerobic training 
decreases circulating antioxidant concentrations and impairs endothelial function in forearm 
vessels (Bergholm et al. 1999). ]_~Iowever, a recent study reported that a physically active 
lifestyle was related to a lower CVD risk and Lower oxidative stress (Phil et al. 2003). 
Dietary Approaches 
Many approaches regarding dietary intake have been investigated to determine which 
components provide protection against CVD. Since the antioxidant effect of phytochemicals 
may be additive or synergistic, it is important to consume whole foods, such as fruits and 
vegetables, rather than pills or e~: tracts. The benefit of a diet rich in fruits and vegetables is 
attributed to the complex mixturE~ of phytochemicals in whole foods compared to individual 
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supplements (Liu 2003). This the;ory is supported by a small study of men and women given 
gazpacho, a Mediterranean vegetable soup rich in vitamin C, who exhibited a reduction in 
oxidative stress and biomarkers of inflammation (Sanchez-Moreno et al. 2004). Likewise, 
fruit and vegetable consumption ~a~as shown to increase glutathione peroxidase activity and 
resistance of plasma lipoproteins t:o oxidation more efficiently than supplemental vitamins 
and minerals (Dragsted et al. 200~~~). Thus, increasing vegetable consumption may greatly 
improve longevity and prevent o~~idative stress-induced diseases. 
Dietary sources rich in fla:~~onoids, including apples, onions, red wine, chocolate, red 
fruits, citrus fruits, and tea, have 'been shown to be cardioprotective. Elderly women who 
consumed strawberries, spinach, or red wine, rich in antioxidant phenolic compounds, 
showed an increase in their antioxidant capacity (Cao et al 1998). In addition, French 
women who consume high amounts of flavonoid-rich foods are at less risk for CVD and have 
lower systolic blood pressure than women who consume low amounts of these foods 
(Mennen et al. 2004). 
The dietary supplementation of lycopene (3 9.2-75.0 mg/day), a carotenoid available 
in tomato products, was shown to significantly reduce serum lipid peroxidation and LDL 
oxidation, yet provided no effect on serum TC or LDL-C (Agarwal and Rao 1998). 
Likewise, the inhibition of lipid peroxidation by polyphenolic antioxidants derived from 
products, such as tea and chocol~~~te has also been documented (CJelekjnse et al. 1999; 
Hodgson et al. 2000). However, in one study the regular ingestion of green or black tea did 
not alter the urinary excretion of ]~~ 2-isoprostanes, a marker of in vivo lipid peroxidation, in 
subjects with mildly elevated blood pressure or serum TC concentration (Hodgson et al. 
2002). Interestingly, cocoa products, rich in flavonoids, were shown to protect LDL from 
oxidation, but had no effect on F2-isoprostanes or other markers of inflammation (Mather et 
al. 2002). Additionally, wan et ,~.1. (2001) found that cocoa powder and dark chocolate may 
favorably affect CVD risk factors by reducing LDL oxidative susceptibility, increasing total 
antioxidant capacity and HDL-C concentration, but not adversely affect prostaglandins. 
In addition to a diet rich ~~n antioxidants, moderate alcohol intake has also been shown 
to provide protection against CV~]D. In a randomized crossover study investigating the effect 
of moderate alcohol consumptio:r~ on CVD risk along with a controlled diet reported a 
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protective effect on serum lipids and lipoproteins. Consumption of 15-30 grams (or 1-2 
drinks/day) of alcohol per day by :postmenopausal women improved plasma LDL-C and 
HDL-C and apolipoprotein A-I arld B concentrations (Baer et al. 2002). Procyanidins, the 
antioxidant predominant in wine, :have been shown to be effective in preventing lipid 
oxidation of foods while in the digestive tract, thus preventing the rise in postprandial 
hydroperoxides (Ursini et al. 199 ~►). In addition, several studies have shown an increase in 
plasma antioxidant capacity follo~Ning wine intake (Maxwell et al. 1994; Whitehead et al. 
1995). Studies with rabbits fed a :high cholesterol diet have shown that grapeseed 
procyanidins are strongly protect~i~ve in reducing plasma lipid peroxides and inhibit lipid-
laden foam-cell deposition (Ursir~:i and Sevanian, 2002). furthermore, a study with pre- and 
postmenopausal women given lyc~~philized grape powder, rich in a variety of polyphenols, 
favorably altered lipoprotein markers, oxidative stress, and inflammatory markers (Zern et al. 
2005). Interestingly, ingestion oi' dietary polyphenols, including wine, cocoa, or tea, along 
with a meal rich in oxidizable lipids, improves endothelial dysfunction, lowers the 
susceptibility of LDL lipids to ox:~idation, and may act as modulatory signaling molecules 
(Sies et a1. 2005). 
The consumption of plant stanol or sterol esters incorporated into food products, such 
as margarine and yogurt, is also a.n effective and safe method of lowering LDL-C (Thompson 
and Grundy 2005). Nonesterified, nonhydrogenated plant sterols from soybean oil, when 
incorporated to a low-fat milk prc►duct, has shown potential to substantially reduce LDL-C in 
mildly hypercholesterolemic individuals (Thomsen et al. 2004). This is possibly due to the 
ability of plant sterols to inhibit c;'holesterol absorption by competing for esterification in the 
enterocyte of the small intestine. 
Another dietary modification is the inclusion of lignans found in flaxseed that have 
been shown to lower LDL-C (Jenkins et al. 1999). In a double-blind randomized study, 40 
grams were given to postmenopa.~~sal women and compared with awheat-base control for 
three months. The subjects on tl~~e flaxseed regimen exhibited a reduction in LDL-C by 4.7% 
and TG by 12.8%. In addition, a.p~~lipoprotein A-1 and apolipoprotein B concentrations were 
significantly reduced by 6% and '7..5%, respectively (Lucas et al. 2002). Lignans are being 
increasingly incorporated into thE; diet for their health properties, such as antitumorgenic 
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(Thompson et al. 1996), estrogenic or anti-estrogenic (Collins et ai.1997), and antioxidant 
properties (Prasad 1997; Prasad 2,000; Kitts et al. 1999). Thus, uses of plant sources, such as 
nuts, legumes, soy, and vegetable- oils, that provide lignans, may provide a variety of health 
benefits including prevention of CVD (Hu 2003). This may be partly due to incorporating 
high proportions of omega-3 fatty acids into serum lipids, which in turn is associated with a 
substantially reduced risk of death (Erkkila et al. 2003). In addition, diets low in saturated fat 
and cholesterol have been shown to promote weight loss and reduce cardiovascular markers 
(Yu-Poth et al. 1999). Lastly, various sources of protein have different effects on CVD; 
replacing refined carbohydrates ` with protein sources low in saturated fat has been shown to 
be beneficial in cardiovascular health (Hu 2005). Therefore, the use of plant sources low in 
saturated fat but rich in omega-3 fatty acids and protein may decrease CVD risk. 
Soy Protein 
A large body of evidence has established a role for soy in CVD risk reduction, 
particularly through lipid reduction (Clarkson 2002). Epidemiological studies have shown 
that the consumption of soy and/or isoflavones is inversely associated with circulating total 
(Nagata et al. 1998) or LDL-C (J~Io et al. 2000) and TG (de Kleijn et al. 2001), and positively 
associated with HDL-C (Goodman-Gruen and Kritz-Siverstein 2001). 
A meta-analysis reported that an average of 47 g soy protein per day resulted in 
reductions of 9.3 % in circulating TC, 12.9% LDL-C, and 10.5 % in TG (Anderson et al. 
1995). This evidence contributed to the approval of the food label claim by the Food and 
Drug Administration for reduced risk of heart disease on foods that contain >6.25 g of soy 
protein per serving, assuming 4 servings or 25 g of soy protein intake daily (Food and Drug 
Administration 2002). The American Heart Association recommends individuals at high risk 
for CVD with elevated total and. LDL-C to consume soy protein containing isoflavones along 
with other heart-healthy dietary modification and increased exercise (Krauss et al. 2001). 
Epidemiological research has provided clear evidence that the consumption of soy 
foods may reduce the risk of C`TD in Chinese women (zhang et al. 2003). The Shanghai 
Women's Health Study reported that the usual intake of soy foods was inversely associated 
with both systolic and diastolic blood pressure, especially in elderly Chinese women (Yang et 
al. 2005). A population-based cross-sectional study of men and women in the Hong Kong 
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Chinese population also found higher soy intake was related to a less atherogenic plasma 
lipid profile (Ho et al. 2000). Interestingly, soy and isoflavone intake has been shown to be 
associated with a reduced risk of cancer; ovarian cancer in southeastern Chinese women 
(Zhang et al. 2004). In addition, it is speculated that breast cancer protection in Asian 
women consuming a traditional soy-containing diet is derived from early exposure to 
soybean products containing geni_stein (Lamartiniere 2000). 
Flavonoids and isoflavones, components of soy, may be responsible for protecting 
individuals from CVD either by favorably affecting blood lipids or by reducing oxidative 
stress, acting as antioxidants. Annong the Japanese population, flavonoid and isoflavone 
intake is the main component among phytochemicals with antioxidant potential in the diet. 
Evidence suggests a high consurription of both flavonoids and isoflavones by Japanese 
women may contribute to a Iowe;r incidence of CVD compared with women in western 
countries (Arai et al. 2000). The Oxford arm of the European Prospective Investigation into 
Cancer and Nutrition showed associations of moderate intakes of soyfoods, as part of a 
regular diet, with favorable blood cholesterol concentrations. Mean plasma L.DL-C 
concentration in women with a soy protein intake >6 g/d was 12.4% lower than in women 
who consumed <0.5 g/d (Rosell et al. 2004). 
Hypercholesterolemic subjects given 3 0-5 0 g of soy protein/day along with a 
cholesterol-lowering diet significantly reduced LDL-C and total homocysteine concentrations 
without increasing lipoprotein (a) concentrations, suggesting an antiatherosclerotic effect 
(Tonstad et al. 2002). However, Engleman et al. (2005) reported soy protein isolate with 
isoflavones had no significant effect in reducing oxidative damage or favorably altering 
blood lipids in postmenopausal women. Likewise, Vega-Lopez et al. (2005) concluded that 
diets high in soy protein or isofl~ivones derived from soy had little effect on plasma 
antioxidant capacity or biomarke;rs of oxidative stress. 
Soy protein was shown to affect serum lipid profiles in a beneficial direction for CVD 
risk in healthy, young men (McVeigh et al. 2006). The consumption of 20 grams of soy 
protein per day for six weeks, in,~tead of animal protein, reduced non-HDL-C by 2.6% 
(Teixeira et al. 2000). In addition, male type 2 diabetics benefited from isolated soy protein 
compared with casein by reductions in the TC-to-HDL-C and LDL-C-to-HDL-C ratios and 
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increased HDL-C concentration (Teixeira et al. 2004). These findings suggest that isolated 
soy protein may help patients at risk for CVD. 
There are several mechanisms by which soy protein may affect lipid metabolism. 
Soy protein peptide chains may up-regulate LDL receptors, thereby stimulating gene 
expression of key enzymes and proteins in lipid metabolism (Tovar et al. 2002; Igbal et al. 
2002; Iritani et al. 1997). It is also speculated that soy protein may improve blood lipid 
profiles by altering LDL receptor• quantity or activity (Baum et al. 1998). Soy protein 
peptides have been shown to regulate cholesterol homeostasis in vitro (Lovati et al. 2000). 
Lastly, the amino acid profile of soy differs from that of animal protein and thereby may 
have an effect on lipid metabolism. The amino acids lysine and methionine have been shown 
to have hypercholesterolemic effects in rabbits, while arginine showed the opposite effect 
(Kurowska and Carroll 1994, Huff et al. 1977). This evidence led to the hypothesis that 
because soy has a higher ratio of arginine-to-lysine and methionine, it may explain the 
hypocholesterolemic effect of soy (Erdman 2000). 
It has been shown that soy protein compared to whey protein supported lean mass 
gain and prevented straining-induced drop in antioxidant capacity, suggesting that soy foods 
prevent the risk of exercise-induced increase in oxidative stress (Brown et al. 2004). In 
addition, soy beverage consumption for three weeks (two servings/day, 40 grams protein, 44 
mg of isoflavones/day) was shovvn to exert antioxidant effects and reduced exercise-induced 
oxidant stress in young men (Brown et al. 2004). Moderate intensity, weight resistance 
exercise, combined with 4 weeks of soy consumption, lowered serum peroxide values in men 
(Hill et al. 2004). Similarly, moderate intensity exercise, along with four weeks of soy 
intake, exerted a lowering effect on serum lipid peroxide production in women (Box et al. 
2005). 
The non-protein components of soy, such as saponins, isoflavones, and phytic acid, 
may also have health benefits by affecting serum TC (Greaves et al. 2000). However, 
isoflavones are the most studied component of soy and will be discussed in more detail 
below. 
Soy Isoflavones 
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Stucture and function: Isoflavones are phytoesterogens, agroup of non-steroidal 
plant chemicals (genistein, daidzein, and glycitein) that possess estrogen-like activity. The 
chemical and structural similarity of 17(3-estradiol to equol, a metabolite of daidzein, has led 
to the hypothesis that isoflavones may be responsible for the hypocholesterolemic effect of 
soy (Setchell 1998). Specifically, it is the presence of the phenolic ring and the distance 
between the hydroxyl groups that makes the isoflavones similar to estrogen (shown in Figure 
6). 
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Figure 6. Chemical and structural similarity of estrogen and isoflavones. 
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Genistein and daidzein, the two predominant isoflavones in soy, have been estimated 
to exert 10"2 to 10-3 of the activity of 17R-estradiol (Miksiceck 1994). However, the 
isoflavone concentration in circulation among those consuming the amount of soy present in 
traditional Japanese diets (50-80mg/d) may be 100-fold higher than the concentration of 
endogenous estrogens (Setchell and Cassidy 1999). Thus, the plasma concentration of these 
isoflavones would place them in a biologically effective range, comparable with that of 
endogenous estrogen. However, dietary isoflavones have less biologically relevant 
estrogenic activity in vivo compared to estradiol in postmenopausal women (Teede et al. 
2004). 
Isoflavones and CVD: Across-sectional study examining the association between 
usual dietary isoflavone intake and CVD risk factors (including lipids and lipoproteins, BMI 
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and fat distribution, blood pressure, glucose, and insulin) in 208 postmenopausal women 
reported that subjects with the highest genistein daily intake had significantly lower BMI, 
waist circumference, and fasting insulin than those with no genistein consumption 
(Goodman-Gruen and Kritz-Silverstein 2001). In addition, genistein, daidzein, and total 
isoflavone intake were each positively associated with higher HDL-C and negatively 
associated with post challenge insulin, suggesting a protective role of dietary isoflavones 
from soy intake against CVD risk factors in postmenopausal women. Intake of soy protein 
v~~ith low and high isoflavone (1.3 9 mg and 2.25 mg isoflavones/g soy protein, respectively) 
content for six months decreased risk factors (6% reduction in TC and 7% reduction in non-
HDL-C) associated with CVD in postmenopausal women (Potter et al. 1998). Similarly, the 
Framingham Offspring Study (de Kleij n et al . 2001) provided evidence that high intakes of 
phytoestrogens in postmenopausal women were associated with reduced risk of CVD. 
However, estimated dietary intake of phytoestrogens in healthy postmenopausal American 
Caucasian women in is <1 mg/day. In contrast, a 24-week study indicated that isoflavone-
rich and isoflavone-poor soy protein had no effect on lipid profiles in perimenopausal women 
(Dent et al. 2001), suggesting that postmenopausal women may be more responsive to soy 
isoflavones than perimenopausal women. Soy protein with intact isoflavones, compared to 
soy protein devoid of isoflavones, increased HDL-C and apolipoprotein A-I concentrations, 
but did not influence LDL-C or fibrinogen in normolipidemic, healthy subjects (Sanders et 
al. 2002). wangen et al. (2001) concluded that although the consumption of isoflavones as a 
constituent of isolated soy protein resulted in insignificant improvements in the lipid profile 
of normocholesterolemic and mildly hypercholesterolemic postmenopausal women, the 
consumption of soy foods over many years in conjunction with other lipid-lowering 
strategies may lower CVD risk. 
Soy protein, independent of its isoflavone component, shifted LDL particle 
distribution to a less atherogenic pattern in hypercholesterolemic men and women 
(Desroches et al. 2004). Ameta-analysis by Zhuo et al. (2004) showed that with identical 
soy protein intake, a high isoflavone intake led to a significantly greater decrease in LDL-C 
than a low isoflavone intake, demonstrating that isoflavones have LDL-C-lowering effect 
independent of soy protein. Lastly, in a more recent meta-analysis of twenty-three 
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randomized controlled trials from 1995 to 2002, soy protein containing isoflavones were 
shown to significantly reduce serum TC, LDL-C, and TG, and significantly increase HDL 
cholesterol. Importantly, the changes were related to the level and duration of soy 
isoflavones intake, the sex and initial serum lipid concentration of the subjects (Zhan and Ho 
2005). Conversely, another meta-analysis often studies concluded that the consumption of 
soy-associated isoflavones is not related to change in LDL-C or HDL-C (Weggemans and 
Trautwein 2003). Likewise, another meta-analysis of seventeen clinical trials confirmed that 
isoflavones in the form of tablets, isolated soy protein, or soy diets with up to 150 mg/day 
had no statistical or clinical benefit on serum lipids (Yeung and Yu, 2003). Therefore, the 
effect of isoflavones on serum lipids warrants further investigation. 
Discrepancies among the findings of these clinical studies may be attributed to 
individual variability, baseline cholesterol concentrations, dietary intake of other 
foods/nutrients, use of medications, isoflavone metabolizing capacity, and genetics. Equol 
(shown in Figure 6) a gut bacteria metabolite of daidzein, has a greater binding affinity to 
estrogen receptors and a greater antioxidant capacity compared to daidzein (Bingham et al. 
2003). Interestingly, individuals vary in their ability to synthesize equol (Rowland et al. 
2000), suggesting that responsiveness to isoflavones may vary depending on an individual's 
equol-synthesizing capacity (Setchell et al. 2002). A large (n=117) randomized, double-
blind, placebo-controlled, crossover dietary intervention trial demonstrated that isoflavone 
supplementation had no effect on lipid or other biomarkers of CVD risk in postmenopausal 
women, but increased HDL-C in an estrogen receptor ~ gene-polymorphic subgroup (Hall et 
al. 2006). This study suggests that polymorphisms in genes may determine an individual's 
response to estrogen or isoflavone supplementation. 
Mechanisms responsible for the effects of soy isoflavones on the lipid profile are 
currently being explored. Isoflavones from intact soy foods may act as a natural selective 
estrogen receptor modulator, and exert an effect on lipid metabolism similar to endogenous 
estrogen. Results from asix-month trial with postmenopausal women indicated that soy 
protein, with different amounts of isoflavones (56 vs. 90 mg of isoflavones), decreased the 
risk of CVD by improving blood lipid profiles (Baum et al. 1998). Researchers reported that 
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the mechanism by which apoplipoprotein B-containing lipoproteins were depressed may be 
due to alterations in LDL receptor quantity or activity. 
Isoflavones may have an effect on lipogenesis and lipolysis. Incubation of isolated 
rat adipocytes with genistein restricted glucose conversion to total lipids, either in the 
absence or presence of insulin (Szkudelska et al. 2000). Thus, the anti-lipogenetic action of 
genistein may related to an alteration in glucose transport and metabolism, in addition to its 
effect on restricting fatty acid synthesis. 
Isoflavones and inflammation: Chronic inflammation is a major contributor to 
atherosclerosis and CVD (Libby et al. 2002). An important marker of inflammation is 
elevation in serum CRP (Bassuk et al. 2004), an acute-phase reactant secreted by hepatocytes 
in response to proinflammatory cytokines such as IL-6. In several epidemiologic studies, 
CRP was shown to be a strong, independent predictor of CVD risk in both men and women 
(Ridker et al. 2001; Rifai et al. 2002; Ridker et al. 2002, Ridker et al. 1997). The mechanism 
by which inflammation increases CVD risk is not known. However, it is possible that 
inflammation may adversely affect lipid metabolism. During periods of acute inflammation, 
lipid metabolism is altered to reflect a proatherogenic profile including: increased TG, 
decreased HDL-C, and the appearance of small, dense LDL particles (Khovidhunkit et al. 
2004; Khovidhunkit et al. 2000; Cabana et al. 1989). 
Recently, isoflavones have been shown to have a beneficial effect on CRP 
concentration, a classic downstream marker of inflammation which mediates the initiation 
and propagation of atherosclerotic plaques (Hall et al. 2005). However, isoflavones have not 
been shown to have similar effects on other inflammatory markers in postmenopausal 
women. For example, in a different study with hypercholesterolemic adults on a cholesterol-
lowering diet, the treatment of added soy with and without isoflavones, or milk protein, did 
not affect lipids or inflammatory markers (Hilpert et al. 2005). Regardless of the protein 
source, individuals with low CRP responded with a significant decrease in LDL-C and in the 
LDL:HDL ratio, whereas those with high CRP had a significant increase in LDL-C, the 
LDL:HDL ratio, apolipoprotein B, and Lp(a) compared with the initial run-in diet Therefore, 
inflammation may not only attenuate lipid responses, but also aggravate dyslipidemia in 
hypercholesterolemic individuals. 
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Based on the relationship between inflammation and vascular function, some studies 
evaluating the effect of soy isoflavones on vascular function have shown protective effects 
(Squadrito et al. 2002; Squadrito et al. 2003; Cuevas et al. 2003), while others have not (Hale 
et al. 2002; Simons et al. 2000; Teede et al. 2001). However, the majority of studies were 
short-term and enrolled a small number of subjects. Evidence from along-term study with 
monkeys showed that soy protein consumption with modest isoflavone content (0.94-1.88 
mg of isoflavones/g protein) inhibited the early progression of coronary artery atherosclerosis 
(Adams et al. 2005). In one study of postmenopausal women, the daily consumption of soy 
protein with isoflavones resulted in positive vascular effects that were independent of lipid 
and antioxidant effects (Steinberg et al. 2003). Likewise, the beneficial effects of isoflavones 
in postmenopausal women could be related to platelet function, as evidenced by a negative 
relation between isoflavone treatment and platelet thromboxane A2 receptor density (Garrido 
et al. 2006). These novel effects may be above and beyond those of improving the more 
common CVD risk factors, such as blood pressure and TC. However, in a large, one-year, 
double-blind clinical trial, Kreijkamp-Kaspers et al. (2005) reported that soy protein with 
isoflavones provided no beneficial effects on vascular function in older postmenopausal 
women. Likewise, a recent eight-week study in 89 healthy postmenopausal women given 
fruit cereal bars with and without isoflavones (50 mg/d) reported no effect on plasma Hcy 
concentration, an independent ri sk factor for CVD, which also may be related to vascular 
function (Reimann et al. 2006). 
Isoflavones and oxidative stress: Although many in vitro studies have shown that 
flavonoids in legumes and soybean products inhibit the oxidation of lipoproteins [via 
inhibiting the oxidative modification of LDL by macrophages (Kapiotis et al. 1997) and 
enhancing resistance of LDL to oxidation (Kanazawa et al. 1995)], there is no clear evidence 
of free radical-scavenging antioxidant effects of flavonoids or their metabolites in vivo. Two 
rat studies by Khan and Sultana (2004) suggest that isoflavones act as potent 
chemoprotective agents against potassium bromate- and ferric nitriloacetate-mediated renal 
oxidative stress, toxicity, and subsequent cell proliferation. However, isoflavone 
supplementation for three weeks in diabetic rats had no effect on reducing oxidative stress 
(Hsu et al. 2003). Similarly, no effect on erythrocyte antioxidant enzyme activities was 
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found in a six-month study of isoflavone supplementation in postmenopausal women (Hsu et 
al. 2001). Isoflavones in soy protein isolate consumed for six weeks were not shown to exert 
a significant effect in reducing oxidative damage in postmenopausal women (Engleman et al. 
2005). 
However, some studies support the antioxidant effects of isoflavones. Genistein was 
shown to be beneficial in preventing oxidative stress in cortical neuronal cells in vitro (Sonee 
et al. 2004), providing evidence that isoflavones may play a protective role in the central 
nervous system. In a three-week pilot study, isoflavones were shown to decrease oxidative 
DNA damage in men and women, but had no effect on ~-isoprostane levels (Djuric et al. 
2001). Thus, isoflavones appear to have free radical quenching ability (Mitchell et al. 1998; 
Arora et al. 1998); genistein and daidzein have been shown to prevent 8-OHdG formation in 
cells and DNA exposed to oxidants (Giles and Wei 1997). Moreover, the protective effect of 
both genistein and daidzein against DNA oxidative darr~age are exhibited at concentrations 
reachable in plasma after soy consumption (Foti et al. 2005). This demonstrates that the 
antioxidant activity of isoflavones could contribute to the health benefits of soy. 
The antioxidant action of isoflavones and their metabolites inhibited the oxidation of 
LDL, exerting an antiatherosclerotic effect, in a rabbit model (Yamakoshi et a12000). The 
long-term supplementation of soy isoflavones to rats resulted in decreased oxidative stress, 
improved endothelial function, and reduced blood pressure (Mahn et al. 2005). Oxidative 
damage was decreased in men who consumed one liter of soy milk daily for four weeks 
(Mitchell and Collins 1999). Isoflavones may also decrease oxidative stress indirectly by 
improving antioxidant status (Cai and Wei 1996). Likewise, soy product supplementation in 
humans has been shown to decrease the rate at which lipids are oxidized (Tikkanen et al. 
1998 and Wiseman et al. 2000). Collectively, these results indicate that along-term soy 
isoflavone supplement trial in humans is warranted. 
Mechanisms responsible for the effects of soy isoflavones on oxidative stress are still 
unclear. Wiseman et al. (2000) demonstrated that the consumption of naturally occurring 
isoflavones from soy foods reduced lipid peroxidation in vivo and increased the resistance of 
LDL to oxidation, measured by plasma concentration of F2-isoprostanes (8-epi-prostaglandin 
Fla) and resistance of LDL to copper-ion-induced oxidation. These results suggest that 
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isoflavones may function as an antioxidant to reduce formation of the preformed lipid 
hydroperoxides. Similarly, Nhan et al. (2005) reported in a small study of premenopausal 
women that isoflavones from soymilk supplementation reduced lipid peroxidation, measured 
by urinary F2-isoprostanes, in an age-dependent manner, with greater effects in older women 
and with lower doses of isoflavones. In vitro studies suggest that genistein and daidzein 
inhibit LDL oxidation in the subendothelium of vessels in a similar manner to that of vitamin 
E (Hodgson et al. 1996). Studies in rats indicated that feeding an isoflavone-rich soy protein 
isolate significantly inhibited LDL oxidation after LDL particles are isolated from serum 
(Anderson et al. 1999). Thus, isoflavones may be transported in LDLs and may act like 
antioxidant vitamins to inhibit oxidative damage. The protective effect from soy isoflavones 
may be due to altering LDL particle size, which may influence resistance to oxidation 
(Tikkanen et al. 1998). Interestingly, esterified isoflavones have been shown to be 
incorporated into LDL ex vivo, resulting in greater oxidative resistance. However, this effect 
has not been validated in vivo (Meng et al. 1999). Therefore, the hypocholesterolemic effect 
of soy foods is likely dependent on the presence of soy protein with isoflavones intact 
(Wagner et al. 2003). However, it is important to note that there is evidence that the 
substitution of soyfoods for animal products, regardless of isoflavone concentration, reduces 
CVD risk because of reductions in blood lipids, oxidized LDL, Hcy, and blood pressure 
(Jenkins et al. 2002). 
Adverse effects of isoflavones: Although there are many benefits of soy consumption, 
there is still concern regarding potential adverse effects of over consumption. It is important 
to note that some researchers have demonstrated that genistein and daidzein may be 
carcinogenic in estrogen-sensitive organs, although isoflavones are generally 
chemoprotective compounds. In vitro evidence indicates that oxidative DNA damage due to 
isoflavone supplements plays a role in tumor initiation and cell proliferation via estrogen 
receptor-estrogen response element binding, thereby inducing tumor promotion and/or 
progression, resulting in cancer of estrogen-sensitive organs (Murata et al. 2004). Likewise, 
studies have shown that genistein and/or daidzein induce cancers of reproductive organs in 
rodents, such as the uterus (Newbold et al. 2001) and vulva (Thigpen et al. 2001). In 
addition, genistein was shown to have tumor-enhancing effects on breast tissue (Allred et al. 
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2001) and the colon (Rao et al. 1997). Thus, estrogen-like substances, such as isoflavones 
and their metabolites, may participate in tumor initiation and promotion by causing DNA 
damage and cell proliferation, potentially leading to carcinogenesis. Epidemiological and 
clinical studies suggest that estrogens may exert carcinogenic actions in humans (Bernstein 
and Ross 1993). Ameta-analysis revealed that postmenopausal users of estrogen have an 
increased risk of breast and endometrial cancer (Nelson et ai. 2002). Hence, like endogenous 
estrogens, gennstein and daidzein may have the capacity to produce not only beneficial 
actions, but also adverse carcinogenic effects. However, the amount of isoflavones given in 
animal studies is important to consider. Although these adverse effects have been reported 
from animal studies, there is no evidence of comparable intakes in human studies. 
Summary 
Understanding the effect of isoflavones on menopause-associated risk factors for 
CVD will provide clarity on alternative therapies to hormone treatment. Given that hormone 
therapies increase the risk for breast cancer and other cardiovascular complications, 
alternative therapies hold promise. Long-term consumption of isoflavones is important to 
study to determine their effect on CVD risk factors, such as: oxidative stress, body iron 
stores, and total Hcy concentration, in postmenopausal women. In addition, it is important to 
study the inter-relationship among these factors. 
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EXCESS IRON IS RELATED TO CENTRAL ADIPOSITY BUT NOT TO 
OXIDATI[YE STRESS IN POSTMENOPAUSAL V~OMEN 
A paper ~~to be submitted to the Journal of Nutrition 
Betsy Deardorff, D. Lee Alekel, Laura Hanson; 
Laura Ritiand, Ulrike Genschel, Kenneth Koehler, Manju B. Reddy 
ABSTRACT 
Background: Postmenopausal women are at risk of atherosclerotic cardiovascular disease 
(CVD) due to a decrease in circulating estrogen levels, compromised antioxidant status, and 
an increase in iron stores, oxidative damage, and abdominal fat accumulation. 
Objective: To determine the relationship among excess iron, oxidative stress, and adiposity 
in postmenopausal women. 
Design: Healthy postmenopausal women were recruited for the Soy Isoflavones for 
Reducing Bone Loss study, a randomized, double-blind, clinical trial designed to examine 
the effect of soy isoflavomes on bone. Antioxidant enzymes (superoxide dismutase, catalase, 
glutathione peroxidase), iron status (serum ferritin [SF] and other indices), oxidative stress 
(oxidized LDL [oxLDL], urinary isoprostanes [PGF2a], protein carbonyls, DNA damage), 
and body size and composition (body mass index [BMI], waist circumference [WC], waist-
to-hip ratio [WHR], sagittal diameter, androidal-to-gynoidal fat mass ratio [AGF ratio]) were 
measured at baseline (n=122). Insulin resistance was calculated using the homeostasis model 
assessment (HOMA). Pearson correlation and multiple regression analyses were used to 
determine the contributing CVD risk factors to oxidative stress and central adiposity. 
Results: Iron status was normal based on median SF (53.1 ng/mL), hemoglobin (13.7 g/dL), 
and transferrin saturation (24%) in these women. The medflan BMI=24.9 kg/m2 and 
WHR=0.75; fasting insulin (11.8 mU/mL) and glucose (87.0 mg/dL) were within normal 
limits. Excess iron was not related to oxidative stress but was related positively to central 
adiposity indices (AGF ratio [r=0.28, P<0.01 ], waist fat mass [r=0.24, P<0.01 ], sagittal 
diameter [r=0.18, P<0.05], WHR [r=0.33, P<0.001]), age (i=0.23, P<0.05), and HOMA 
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(r=0.16, P<0.09). Lipid oxidation measures were also associated positively with central 
adiposity. Multiple regression analysis revealed age, LDL cholesterol, and AGF ratio were 
contributors to the overall variance (R2=34%; P<0.0001) in oxLDL, whereas oxLDL, time 
since menopause, fIOMA, HD~L cholesterol, PGF2a, and SF contributed to the overall 
variance (R2=33%; P<_0.0001) in AGF ratio. 
Conclusion: Iron excess was positively associated with central adiposity, possibly mediating 
insulin resistance in these postmenopausal women, but not related to increased oxidative 
stress. Maintaining a favorable lipid prof le, antioxidant and iron status, as well as minimal 
central adiposity, may protect postmenopausal women from chronic disease. 
KEY WORDS Cardiovascular disease, oxidative stress, iron, adiposity, insulin resistance 
INTRODUCTION 
Body iron stores, oxidative stress, blood lipids, and body fat typically increase with 
age, especially after menopause due to the loss of endogenous estrogen production. The 
cessation of menses in postmenopausal women contributes to elevated serum ferritin (SF) 
(Nordbo et al. 1994), as evidenced by postmenopausal women having three-fold greater SF 
compared to premenopausal women (Masse et al. 2004). Although controversial, some 
epidemiological studies show a positive correlation between body iron stores and risk for 
atherosclerotic cardiovascular disease (CVD) (Salonen et al. 1992; Danesh et al. 1999; 
Klipstein-Grobusch et al. 1999), while others state that there is insufficient evidence for this 
relationship (Corti et al. 1997; Eichner et al. 1998). Aspirin intake, shown to reduce the 
incidence of myocardial infarction, was associated with low SF in the Framingham Heart 
Study, indicating a potential role of iron in CVD (Fleming et al. 2001). Finally, elevated SF 
concentration in postmenopausal women was associated with an increased risk of ischemic 
stroke, possibly due to the interaction of other CVD risk factors that accelerate atherogenesis 
by stimulating oxidative stress (Van der et al. 2005; Klipstein-Grobusch et al. 1999). 
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Oxidative stress or compromised antioxidant status has been suggested to be involved 
in the etiology of diseases including cancer, CVD, cataracts, and the aging process (Institute 
of Medicine, 2000). Favorable oxidative status is defined as a balance between reactive 
oxygen species and the antioxidant defense system. Transition metals, such as iron and 
copper, catalyze free radical oxidation of lipids and proteins. Iron, as a prooxidant, may 
contribute to atherosclerosis by promoting oxidative modification of LDL, a key step that 
leads to arterial scarring and infla.:mmation. In the Fenton reaction, free iron catalyzes 
hydrogen peroxide to the harmful hydroxyl radical, resulting in lipid peroxidation. Once 
lipid hydroperoxides accumulate, free iron may directly initiate additional lipid peroxidation 
(Steinberg et al. 1989). 
Some studies disagree regarding the role of iron in oxidative stress. Iron 
supplementation did not increase oxidized LDL (oxLDL) in women with low iron status 
(Derstine et al. 2003; Binkoski et al. 2004). Similarly, Sempos et al. (2001) found no 
evidence that body iron stores were directly related to CHD or indirectly related to oxLDL. 
However, women with high iron stores and elevated total cholesterol (TC) were shown to be 
at greater risk for atherosclerosis compared to those with only elevated iron stores (Kiechel et 
al. 1994). Thus, in a healthy population, iron excess may not be a major concern; however, 
in persons with high oxidative stress and hyperlipidemia, iron excess may place them at 
greater risk for CVD (Reddy and Clark, 2004). Hence, the iron hypothesis first proposed by 
Sullivan (1981), although controversial, suggests that elevated iron stores are causally linked 
to CVD. This hypothesis suggests that oxidative imbalance is the central biologic 
mechanism for the greater incidence of heart disease in men and postmenopausal women 
compared with the lower incidence in premenopausal women. 
Less research has been conducted on the relationship between excess iron and body 
fat distribution, despite the independent association of each factor with CVD risk. A positive 
association between SF and indices of central adiposity (Urakawa et al. 2003; Gillum 2001), 
insulin resistance (Shea et al. 2003; Iwasaki et al. 2005), and metabolic syndrome (Jelin et al. 
2004) suggests a role of excess iron in obesity and CVD. The objective of our study was to 
determine the relationship among atherosclerotic CVD risk factors, particularly oxidative 
stress indices, central adiposity, and body iron stores in postmenopausal women. 
~o 
SUBJECTS AND METHODS 
Study Design 
Postmenopausal women were recruited for the Soy Isoflavones for Reducing Bone 
Loss (SIRBL) study, a randomized, double-blind, three-year clinical trial that was designed 
__ 
to examine the effects of two doses of soy isoflavones on bone loss in postmenopausal 
women. The aim of this ancillary study was to determine the relationship among specific --- --_ 
CVD risk factors at baseline including body iron stores, oxidative stress, and central 
adiposity. 
Subject Selection 
We recruited subjects throughout the state of Iowa and the Sacramento region in 
California through direct mailing lists, stories in local newspapers, local/regional radio 
advertisements, astory on a local television channel, community announcements, 
cooperative extension nutrition and health field specialists, and mailings/flyers at local school 
systems, medical centers/clinics, grocery stores, university campus, public libraries, local 
women's groups, and local businesses (see Figure 1 for subject enrollment flow chart). 
Trained graduate assistants conducted telephone interviews (n=2,411) to screen potential 
postmenopausal women to ensure that they met inclusion/exclusion criteria: 
postmenopausal women, < 65 years of age, had their last menstrual cycle at least 12 months 
ago (cessation of menses from one to eight years), had a body mass index (BMI) (kg/m2) 
ranging from 18.5 through 29.9, free of chronic diseases, non-smoking (not smoked in the 
past 6 months), willing to consume one of three treatments daily for three years, willing to 
discontinue all supplements and take only study supplements provided for three years, 
willing to avoid isoflavone-rich foods, and able to visit our testing facility at designated 
intervals (pre-baseline, baseline, 6 mo, 1 yr, 2 yrs, 3 yrs). We excluded women from the 
study if they had a history of or currently had any of the following conditions: removal of the 
ovaries, hysterectomy, urolithiasis, bone disease, renal disease, cancer, CVD, diabetes 
mellitus, respiratory disease, parathyroid disease, thyroid disease, or liver disease. In 
addition, women were excluded if they used any of the following (currently or within last 12 
months): hormone or estrogen therapy (by mouth or skin patch), selective estrogen receptor 
modulators (SER.Ms), or other hormones. Exclusion criteria also included the use of 
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estrogen or progestogen creams and/or calcitonin currently or within the last six months. We 
also excluded subjects from the study who had any use of bisphosphonates (currently or in 
the past) or current (or within the last three months) use of antibiotics. Likewise, the current 
use of the following was grounds for exclusion: cholesterol-lowering or anti-hypertensive 
medications, herbal therapies, nutritional/dietary supplements, or excessive alcohol intake 
(limit to <7 drinks/wk with no alcohol intake four days prior to blood draws). We also 
excluded subjects with excessive vasomotor symptoms from the study. Lastly, we excluded 
vegans and subjects who had afirst-degree relative with breast cancer from the study. 
Data Collection 
At baseline, we obtained from each subject a health and medical history and a 
nutrition history using interviewer-administered questionnaires. Using a food frequency 
questionnaire from Block Dietary Data Systems (Berkeley, CA), we assessed usual dietary 
intake. We evaluated antioxidant intake both as dietary ingestion only and dietary plus 
supplemental use. Fasted (at least nine hours) blood samples were drawn between 7 and 8 
a.m. and processed as serum, plasma, and erythrocyte samples; we separated serum and 
plasma from whole blood by centrifuging for 15 minutes at (4°C) at 1000 x g and stored 
aliquots at -80°C until analyses. Each subject collected a 24-hour urine sample; we measured 
the total volume and froze aliquots at -20°C until analysis. A certified clinical reference 
laboratory (Laboratory Corporation of America, Kansas City, MO) analyzed each subject's 
serum and plasma for the blood lipid profile (total cholesterol [TC], low-density lipoprotein 
cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C], triacylglycerol [TG]) 
and other blood chemistry markers. We measured oxidative stress indices (protein carbonyls, 
oxidized low-density lipoproteins (oxLDL), urinary isoprostanes, specifically 15-isoprostane 
Fla (PGFZa), 8-hydroxy-2'-deoxyguanosine (8-OHdG), antioxidant enzymes (catalase [CAT], 
glutathione peroxidase [GPX], superoxide dismutase [SOD]), insulin, and SF in the 
laboratory at Iowa State University. We calculated the intra-assay and inter-assay variability 
for each method using a pooled sample as a quality control; these values are listed in Table 1. 
We used the following procedures to analyze oxidative stress indices and antioxidant 
enzymes. To measure antioxidant enzyme (CAT, GPX, and SOD) activity, we used 
erythrocyte lysate and to determine protein carbonyls (expressed as per mg creatinine), we 
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used heparinized plasma (Cayman Chemical Company; Ann Arbor, MI). We measured 
plasma oxLDL (ALPCO Diagnostics; Windham, NH) and urinary isoprostanes, measured as 
15-isoprostanes Fla (PGFZa) (Oxford Biomedical Research; Oxford, MI) using enzyme-linked 
immunoassay (ELISA) kits. Urine is better than blood to quantify PGF2a because some 
factors, such as aspirin, may suppress the circulating concentration (Reilly et al. 1996) and 
urine may be stored for a longer period than serum/plasma without degrading. We measured 
urinary 8-OHdG to assess DNA damage using an ELISA kit (Stressgen Bioreagents; 
Victoria, BC, Canada). We measured SF to determine iron stores using a radioimmunoassay 
(RIA) kit (Ramco Diagnostics; Stafford, TX). We measured fasting insulin using an RIA kit 
(LINGO Research; St. Charles, MO) and calculated the homeostatic model assessment 
(HOMA) of insulin resistance for each subject using the following formula: fasting serum 
insulin (µU/mL) x fasting plasma glucose (mg/dL)/405 (Matthews et al. 1985). 
Both dual-energy x-ray absorptiometry (DXA; Delpi W Hologic Inc; Waltham, 
Massachusetts) and anthropometric measurements were used as indices of central adiposity. 
A certified DXA operator conducted a whole body scan on each subject. We ~~sed this 
technology to assess entral (waist plus hip fat mass__androidal fat) and ynoidal (thigh fat 
mass=gynoidal fat) adiposity using subregion analysis (Discovery Version 12.3:7). We 
calculated the androidal-to-gynoidal  fat mass ~F rat atio for each subject. A trained 
anthropometrist measured standing and sitting heights (Ayrton stadiometer, Model S 100; 
Ayrton Corp., Prior Lake, MN); weight (abco Health-o-meter; Health-o-meter Inc., 
Bridgeview, IL); waist, hip, and abdominal circumferences; sagittal diameter (Holtain-Kahn 
abdominal caliper; Holtain Ltd., Crosswell, Crymych Dyfed, U.K.); we calculated waist-to-
hi'" ratio_.. ~~VHR)_for each  sub' ect. ~` ~I? - ( r-~---- -----  J ---'' 
Statistical Analysis 
Statistical analyses were performed with SAS (Version 9.0). For all results, we 
considered P<0.05 as the level of statistical significance. Pearson correl t' on analysis was 
used initially to examine the correlations among the CVD risk fact~xs for entry into the 
multiple regression models. Multiple regression analysis with protein carbonyls selection 
=- _-____ _.____ _ _ _ 1 
was used to determine the factors related to oxLDL and AGF ratio. The initial variables in 
xhe regr~ssio 1 fo~oxLDL included: age, AGF ratio, SF, LDL-C, and dietary intake of 
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selenium, vitamin_ E,__v_itamin_C',_and beta Ear-otene. The initial variables in the regression 
model for AGF ratio included: age, oxLDL, time since menopause, HDL-C, LDL-C, SF, 
1 -
HOMA, and PG Fla• 
RESULTS 
Subject Cha~actet~istics 
The subjects' descriptive characteristics and daily nutrient intakes at baseline are 
listed in Table 2. The median age of subjects in this study was 55 y (range 47-62 y). The 
range of time since menopause was 1 through 8 y with a median of 3.3 y. The women's BMI 
ranged from normal to overweight (18.9-29.8 kg/m2), with a median of 24.9 kg/m2. A BMI 
greater than 25.0 kg/m2, considered as overweight, was found in 47% of women in this study. 
Dietary intake of macronutrients and selected antioxidant nutrients (vitamins A, C, E, and 
selenium) was within the recommended dietary allowances for these women. Descriptive 
data for iron, adiposity, and oxidative stress indices, and antioxidant enzyme, blood lipid, 
glucose and insulin concentrations, as well as insulin resistance (HOM1~:) are presented in 
Table 3. 
Iron Indices 
Median values for SF (53.1 ng/mL), hemoglobin (Hb) (13.7 g/dL), and transferrin 
saturation (24%) were within the normal range, suggesting that these women did not have 
excess iron conditions. However, a small percentage (3) of women had SF above 140 ng/mL 
and 9% had transferrin saturation under 15%. With the exception of one woman with a Hb 
of 11.4 g/dL, none of them had iron deficiency anemia. 
Oxidative Status 
It is difficult to state whether oxidative status was normal in these women; however, 
values were in the normal range based upon the manufacturers' guidelines. There was a wide 
range of antioxidant enzyme activity among the subjects, but the median values were the 
within normal range for each enzyme : CAT (41.3 ; S . 9-112. ~ nmol/min/mL), SOD (75 5.6; 
27.3 -1874.2 U/mL), and GPX (18 8. S; 91.7 3 0.4 nmol/min/mL). Similarly, the oxidative 
stress indices varied among subjects, but the median values were normal : oxLDL (73.7; 
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31.8-130.6 U/L), PGF2a (2.44; 1.26-5.82 ng/mL), protein carbonyls (6.0; 0.06-67.7 nmol/mg 
protein), and 80HdG (43.7; 14.5-194.8 ng/mL)]. 
Adiposity and Insulin Resistance 
More than a 10-fold variation was found in androidal fat mass (1.09-10.12) compared 
to a 4-fold variation in gyndoidal fat mass (2.44-8.97}. The median AGF ratio was 1.0 kg 
(range 0.45-2.20 kg). The median WHR was 0.75, a level which is not associated with a high 
risk of chronic diseases (Yusuf et al. 2005). Fasting insulin (median 12.8 mU/mL, 
range=4.5-47.2) and glucose (median=87.0 mg/dL, range=66.0-108.0) concentrations were 
also within normal limits. Four of the 122 women had an insulin concentration above 20 
mU/mL and 8 had a glucose concentration above 100 mg/dL, but these women did not have 
values in the diabetic range. The calculated median HOMA was 2.7 (range 0.83 -10.8). 
Correlation among CVD Risk Factors 
Pearson correlation analysis among SF, oxLDL, PGF2a, central adiposity, age, and 
HOMA is shown in Table 4. Serum ferritin was not significantly associated either with 
oxidative stress or antioxidant indices. I-however, it was related to various indices of central 
adiposity; the highest positive correlation (r=0.33; P<0.001) was observed between SF and 
WHR. In addition, SF was correlated with AGF ratio (r=0.23; P <0.01), WaistFM (r=0.24; P 
<0.01), SagDiam (r=0.18; P <0.01), age (r-=0.23; P <0.05), and I-~OMA (r=0.16; P<0.09). 
The lipid peroxidation indicators, oxLDL and PGF2a, were also positively associated with 
central adiposity indices. Specifically, oxLDL was positively associated with AGF ratio 
(r=0.23, P <0.05), WaistFM (r=0.24, P <0.05), and age (r=0.23, P <0.05). Similarly, PGF2a ---- 
was correlated with AGF rata (r=0.32, P <0.01 }, WaistFM (r=0.27, P <0.01), WHR (r=0.3 3, 
P <0.01), and H O MA (r=0.21, P <0.0 5) . 
Contributors to Oxidative Stress and Central Adiposity 
Multiple regression analysis with backward selection was performed to examine the 
potential contributors to factors to lipid peroxidation and central adiposity. The results are 
shown in Table 5. To determine the contributing factors to oxidative stress, we choose 
oxLDL to represent oxidative damage. The variables included in this model are: age, AGF 
ratio, SF, dietary antioxidants (vitamin C, beta-carotene, vitamin E, and seleniumhe). These 
variables contributed 39.3°/® of the variability to oxLDL. However, only age (1.6%), LDL-C 
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(24.8%), and AGF ratio (2.2%) were the only significant contributors to the overall variance 
(R2=34.4%; P<_0.0001) for oxLDL. In this model, SF was not a significant contributor to 
oxLDL. To determine the contributing factors of central adiposity, we choose AGF ratio to 
represent abdominal adiposity because it is assessed via DXA, agold-standard method for 
body composition assessment. Variables included in the AGF ratio model are: age, oxLDL, 
time since menopause, HOMA, HDL-C, LDL-C, PGF2a, and SF. These variables accounted 
for 33% in the variability but only oxLDL (3.0%), time since menopause (1.8%), HDL-C 
(5.7%), SF (4.4%), HOMA (2.6%), and PGF2a (3.5%) showed a significant contribution 
(R2=37.9%; P<0.0001). 
DISCUSSION 
Iron exerts catalytic activity to produce free radicals causing oxidative damage, 
increasing CVD risk. Men and postmenopausal women are at increased CVD risk, which 
may be attributed to elevated iron stores (Nordbo et al. 1994). Serum ferritin is a commonly 
used marker of iron status that accurately reflects iron stores, which may differ by age and 
sex (Zacharski et al. 2000). Postmenopausal women have higher SF levels compared to 
premenopausal women, both in blood donors (43.4 vs. 23.1 µg/L) and in nondonors (71.7 vs. 
32.8 µg/L) (Berge et al. 1994). In our previous study with perimenopausal women, the 
median SF value was lower (27.5 µg/L) (Swain et al. 2002) compared to postmenopausal 
women (45.6 µg/L) (Hanson et al. 2006, In press). 
Epidemiological data, although controversial, suggests a positive correlation between 
excess iron stores and risk for CVD (Salonen et al. 1992; Danesh et al. 1999). Based on the 
association of aspirin with reduced risk of myocardial infarction and reduced iron stores, 
suggests the role of iron in the etiology of CVD. The Framingham Heart Study reported that 
aspirin supplementation lowered SF, supporting epidemiologic studies regarding associations 
between elevated SF and CVD (Fleming et al. 2001; Salonen et al. 1992; Danesh et al. 1999). 
In the presence of classic CVD risk factors, SF may adversely affect ischemic heart disease 
(Klipstein-Grobusch et al. 1999). The Bruneck Study also showed that SF was one of the 
strongest indicators of carotid artery disease in both men and women. In addition the 
predictive significance of SF was found to be synergistic with hypercholesterolemia (Kiechl 
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et al. 1994). Since iron stores, TC, and LDL-C increase with age (Berge et al. 1994), this 
synergistic effect is of concern in postmenopausal women. 
However, in normal, healthy individuals, free iron is not readily available because 
body iron is either bound to transferrin or stored as ferritin (Meyers 2000). We found no 
significant relationship between SF and oxidative stress or antioxidant enzymes, suggesting 
iron was not involved in free radical generation in these women. The women in our study 
were early postmenopausal, with a median SF concentration of 53 ng/mL, which is not 
considered an iron excess state. Thus, iron excess may not be of maj or concern in a healthy 
population. However, individuals with high oxidative stress combined with hyperlipidemia 
may be at high risk for CVD (Reddy and Clark, 2004). In women with low iron status, iron 
supplementation did not increase the susceptibility of LDL to oxidative modification 
(Binkoski et al. 2004), suggesting that subjects who need iron supplementation should not be 
concerned about oxidization of LDL. In addition, iron status was not associated with LDL 
oxidative susceptibility in healthy men and women (Derstine et al. 2003). Sempos et al. 
(2001), in an extension review, concluded that excess iron stores were not related to oxLDL 
or coronary heart disease. It should be noted that the women in our study were not severly 
hypercholesterolemic (LDL cholesterol <160 mg/dL, TG <200 mg/dL), nor had elevated iron 
stores, and thus were not likely to be very susceptible to oxidative damage. 
Although iron was not related to oxLDL, we found excess iron was positively 
associated with the AGF ratio (Table 4 and Sb). Since central adiposity is a well-known risk 
factor for atherosclerotic CVD, the association of SF to the AGF ratio suggests a role for iron 
in androidal fat accumulation. Our results are supported by data indicating a direct 
correlation of elevated SF concentration with visceral fat and subcutaneous fat area using 
computed tomography (Iwasaki et al. 2005). Further, elevated SF is associated with 
decreased insulin sensitivity and increased fasting plasma insulin and glucose, abnormalities 
which may lead to increased adiposity (Gillum 2001). Similarly, our results showing the 
relationship (trend, p=0.09) between SF and HOMA also suggest that iron status may play a 
role in insulin resistance. Likewise, data from the Third National Health and Nutrition 
Examination Survey shows that elevated iron stores, reflected by SF, was positively 
associated with the prevalence of the metabolic syndrome and insulin resistance (Jelin et al. 
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2004). In addition, SF concentration was also related to the degree of insulin resistance in 
Chinese women, after adjusting for age, BMI, and menopausal status (Sheu et al. 2003) . In 
contrast, Chambers et al. (2006) found that serum iron was inversely correlated with BMI, 
waist circumference, and fat mass among Hispanic women. However, SF was not measured 
in this study and hence the authors caution against over interpretation of their results. In 
addition, ethnic or cultural differences may influence the association between iron stores and 
indices of adiposity. 
One possible mechanism might be that excess liver iron stores may reduce the ability 
of insulin to suppress hepatic glucose production and interfere with hepatic insulin clearance, 
thereby leading to peripheral hyperinsulinemia (Fernandez-Real et al. 1998; Niederau et al. 
1984). In addition, excess iron may reduce pancreatic insulin secretion (Nilson et al. 2003), 
further contributing to insulin resistance. Finally, elevated free fatty acids may damage 
pancreatic beta cells, interfere with muscle glucose uptake, and contribute to insulin 
resistance (Tuomainen et al. 1997}. 
There is a clear association between iron overload conditions and insulin resistance. 
which may result in diabetes. For example, type 2 diabetes is a common problem in 
hemochromatosis (Witte et al. 1996) and thalassemia (Cario et al. 2003) patients, conditions 
of iron overload. However, elevated SF also has been observed in individuals without 
diabetes, but with decreased insulin sensitivity (Tuomainen et al. 1997; Haap et al. 2003) and 
in women with gestational diabetes (Lao et aI. 2001), as well as individuals with type 2 
diabetes (Fernandez-Real JM et al. 2002). Finally, elevated SF concentration has been 
shown to precede the development of diabetes in two prospective studies of Finnish men 
(Salonen et al. 1998) and U.S. nurses (Jiang et al. 2004). Although the subjects in our study 
were healthy, we nonetheless found that both HOMA and SF contributed to central adiposity, 
confirming the interrelationship among iron, adiposity, and insulin resistance. The HOMA 
model has been used in cohort and epidemiological studies as a useful tool to assess insulin 
resistance. HOMA has an advantage over other models because it requires only a single 
plasma sample for insulin and glucose determination (Wallace et al. 2004). 
Adipose tissue is highly metabolic and abdominal fat induces oxidative stress, which 
in turn has been shown to cause insulin resistance in men (Urakawa et al. 2003). In both men 
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and women, a high waist circumference was associated with elevated oxLDL, independent of 
BMI (Weinbrenner et al. 2006), illustrating that the abdominal fat mass may induce a greater 
degree of oxidative stress. Our results support the idea that, in addition to high LDL-C, 
central adiposity (AGF ratio) is one of the key factors related to elevated oxLDL. 
As expected, our study showed that oxLDL, time since menopause, HOMA, HDL-C, 
and PGF2a contributed to central adiposity (Table 4B), but interestingly SF was one of the 
significant contributing factors to the AGF ratio and also was positively correlated with other 
central adiposity indices. Perhaps excess iron exacerbates central adiposity by aggravating 
insulin resistance, but it is also possible that central adiposity may contribute to excess iron 
stores. On the other hand, SF is an acute-phase reactant or inflammatory marker and may be 
elevated in conditions not associated with excess body iron stores. Overweight and obese 
individuals are characterized as having glow-grade inflammatory response (Vega 2004). 
Since obesity is an inflamatory state, it may increase bolo ferritin rather than iron-bound 
ferritin. Yet, we do not have a method to differentiate bolo and iron-bound ferritin. Thus, 
increased SF may reflect obesity-induced inflammation, a relatively new factor in the 
etiology of CVD (van der et al. 2005). Since iron is involved in the immune process, an 
increased demand for iron may result in low serum iron (Ganz 2003). An inverse 
relationship of serum iron with BMI, waist circumference, and fat mass supports this concept 
(Chambers et al. 2006). 
We demonstrated an association among CVD risk factors, but since this was an 
observational study, we cannot establish cause and effect. However, future research is 
needed to understand the mechanisms) involving iron, insulin resistance, and obesity. 
Individuals with hypercholesterolemia, type 2 diabetes, excess iron stores, and/or smokers (at 
increased risk of oxidative stress) may be good candidates for future research in this area. 
In conclusion, iron excess was positively associated with central adiposity, possibly 
mediating insulin resistance in these postmenopausal women. I~Tonetheless, excess iron 
stores were not related to increased oxidative stress (oxidative damage indices or antioxidant 
enzymes). Our study suggests that maintaining a favorable lipid profile, antioxidant and iron 
status, as well as minimal central adiposity, may protect postmenopausal women from 
chronic disease. 
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FIGURE 1 
Subject enrollment flow chart 
Completed telephone screening = 2,411 
Completed pre-baseline screening = 241 
V 
Excluded = 119 
V
Enrolled, completed baseline testing = 122 
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TABLE 1 
Intra-assay and inter-assay variability i
Assay Intra-assay (%) Inter-assay (%) 
Protein Carbonyls 2.5 3.4 
Oxidized LDL 4.8 5.2~ 
Urinary Isoprostanes 3.2 17.0 
8-hydroxy-2' -deoxyguanosine 2.5 3.2 
Catalase 5.3 8.4 
Glutathione Peroxidase 4.0 7.5 
Superoxide Dismutase 8.7 10.9 
Serum Ferritin 4.9 5.6 
1 Calculated from a pooled sample as a quality control in each assay 
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TABLE 2 
Subject characteristics 
Measurement (n = 122) Median s Range (min-max) 
Age (y) 552 (47.3-61.8) 
Time Since Menopause (y) 2.7 (1.0-7.9) 
Weight (kg) 68.1 (47.8-89.2) 
Height (cm) 165.6 (150.6-178.4) 
BMI (kg/m2) 24.9 (18.9-29.8) 
Dietary Intake/d2
Energy (KJ) 6649 (1171-19109) 
Protein (g) 64 (20-168) 
Carbohydrate (g) 195 (33-476) 
Fat (g) 67 (17-247) 
Saturated Fat (g) 20 (5-65) 
Iron (mg) 11.4 (3.1-45.6) 
Polyunsaturated Fatty Acids (g) 16.1 (2.5-70.4) 
Vitamin A (RE) 1286 (360-5163) 
Vitamin C (mg) 100 (19-325) 
Vitamin E (mg) 9 (2-38) 
Selenium (µg) 75 (23-227) 
~ Median values are reported for subject characteristics and dietary intake, since most were 
not normally distributed 
2 Dietary intake assessed using Food Frequency Questionnaire (Block Dietary Data Systems) 
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TABLE 3 
Baseline descriptive data (n=122) 
Measurement Median' 
Iron indices 
Ferritin (ng/mL) 53.1 
Hemoglobin (g/dlL) 13.7 
Hematocrit (%) 40.8 
Serum Iron (ug/dL) 80.0 
Transferrin Saturation (%) 24.0 
Oxidative stress indices 
8-hydroxy-2'-deoxyguanosine (ng/mL) 43.7 
Urinary Isoprostanes (ng/mL) 2.44 
Oxidized LDL (U/L) 73.7 
Protein Carbonyls (nmol/mg protein) 6.0 
Antioxidant enzymes2
Catalase (nmol/min/mL) 41.3 
Superoxide Dismutase (U/mL) 755.6 
Glutathione Peroxidase (nmol/min/mL) 188.5 
Central adiposity indices 
Waist Circumference (cm)3 76.7 
Sagittal Diameter (cm) 3 18.6 
Waist-to-hip Ratio 0.75 
Waist Fat Mass (kg) 4 224 
Androidal fat mass (kg) 5.37 
Gyndoidal fat mass (kg) 5.26 
AGF ratio 1.00 
Blood lipids 
Total cholesterol (mg/dL) 205 
Total triacylglycerides (mg/dL) 81 
Range (min-max) 
(4.8-175.1) 
(11.4-16.0) 
(33.5-47.6) 
(31.0-177.0) 
(7.0-56.0) 
(14.5-194.8) 
(126-5.82) 
(31.8-130.6) 
(0.06-67..7) 
(5.9-112.5) 
(27.3-1874.2) 
(91.7-430.4) 
(62.8-98.6) 
(14.4-24.8) 
(0.64-0.91) 
(0.39-5.34) 
(1.09-10.12) 
(2.44-8.97) 
(0.45-2.20) 
(142-285) 
(31-290) 
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LDL cholesterol (mg/dL) 122 (62-173) 
HDL cholesterol (mg/dL) 69 (42-103) 
TC/HDL cholesterol ratio 3.0 (1.9-4.9) 
Other 
Fasting Insulin (mU/mL) 
Fasting Glucose (mg/dL) 
HOMAS
12.8 (4.5-47.2) 
87.0 (66.0-108.0) 
2.72 (0.83-10.8) 
1 Median values are reported for baseline descriptive data, since most were not normally 
distributed 
2n=117 because data for 5 subj ects are missing due to processing errors of erythrocytes at 
time of collection 
3Assessed by anthropometric measurements 
4Assessed by dual energy x-ray absorptiometry 
SHomeostasis Model Assessment of Insulin Resistance (HOMA) calculated as follows: 
Fasting insulin (mU/mL) x Fasting glucose (mg/dL) / 405 (Matthews et al. 1985) 
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TABLE 4 
Correlations between body fat measurements, age, and I~OMA and SF, oxLDL, PGF2« 
SF oxLDL PGF2a 
AGF ratio 0.28** 0.27** 0.32** 
WaistFM 0.24* * 0.26* * 0.27* 
SagDiam 0.18* 0.08 0.17 
WHR 0.33*** 0.23* 0.12 
Age 0.23 * 0.23 * * 0.09 
HOMA 0.21 0.02 0.21 
SF --- 0.06 0.09 
1 Pearson correlation coefficients (* p<0.05, * * p<0.01, * * * p<0.001) 
SF =serum ferritin; oxLDL= oxidized low-density lipoproteins; PGF2a =urinary 
isoprostanes 
AGF ratio = androidal to gynoidal fat mass ratio; WaistFM =waist fat mass; 
SagDiam = sagittal diameter; WHR= waist-to-hip ratio; WaistCirc =waist circumference 
HOMA =Homeostasis Model Assessment of Insulin Resistance 
There were no significant associations between ferritin and oxidative stress indices 
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TABLE 5 
Regression analysed: Cardiovascular disease risk factors 
A. Factors related to oxidative stress, specifically oxLDL 
Overall Model R2 = 36.0%~_~Adj R2 = 34.4%); F (3,118) = 22.15; (p < 0.0001) 
Independent Variable Parameter Percentage Variance 
Estimate Variance ~ valuer Inflation 
Intercept -23.12 
Age 0.7326 1.6 0.086 1.04 
LDL-C 0.3987 24.8 <0.0001 1.06 
AGF ratio 0.8262 2.20 0.046 1.06 
Variables eliminated from the model were: serum ferritin, dietary antioxidants (selenium, 
beta-carotene, vitamin E, vitamin C) 
B. Factors related to central adiposity, specifically AGF ratio 
Overall Model R2 = 29.49% (Adj R2 = 32.98%); F (5,116) = 9.43; (p < 0.0001) 
Independent Variable Parameter Percentage Variance 
Estimate Variance P valuer Inflation 
Intercept 0.7138 
OxLDL 0.003 3 2.97 0.026 1.07 
Time since Menopause 0.0231 1.80 0.081 1.05 
HOMA 0.03 98 2.61 0.03 7 l . l 1 
HDL-C -0.0055 5.74 0.002 1.04 
Urinary Isoprostanes 0.0759 3.46 0.016 1.11 
Serum ferritin 0.0017 4.3 7 0.007 1.04 
Variables eliminated from the model were: age and LDL-C 
1 Multiple regression analysis with stepwise selection. Variables left in model are significant 
at P < 0.05 level 
